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γ-Glutamyl transpeptidase (GGT) catalyzing the cleavage of -glutamyl bond of glutathione 
and its S-conjugates is involved in a number of physiological and pathological processes through 
glutathione homeostasis. Defining its Cys-Gly binding site is extremely important not only in 
defining the physiological function of GGT, but also in designing specific and effective 
inhibitors for pharmaceutical purposes. Here we report the synthesis and evaluation of a series of 
glutathione-analogous peptidyl phosphorus esters as mechanism-based inhibitors of human and 
E. coli GGTs to probe the structural and stereochemical preferences in the Cys-Gly binding site. 
Both enzymes were inhibited strongly and irreversibly by the peptidyl phosphorus esters with a 
good leaving group (phenoxide). Human GGT was highly selective for L-aliphatic amino acid 
such as L-2-aminobutyrate (L-Cys mimic) at the Cys binding site, whereas E. coli GGT 
significantly preferred L-Phe mimic at this site. The C-terminal Gly and a L-amino acid analogue 
at the Cys binding site were necessary for inhibition, suggesting that human GGT was highly 
selective for glutathione (-Glu-L-Cys-Gly), whereas E. coli GGT are not selective for 
glutathione, but still retained the dipeptide (L-AA-Gly) binding site. The diastereoisomers with 
respect to the chiral phosphorus were separated. Both GGTs were inactivated by only one of the 
stereoisomers with the same stereochemistry at phosphorus. The strict recognition of phosphorus 
stereochemistry gave insights into the stereochemical course of the catalyzed reaction. Ion-spray 
mass analysis of the inhibited E. coli GGT confirmed the formation of a 1:1 covalent adduct with 
the catalytic subunit (small subunit) with concomitant loss of phenoxide, leaving the peptidyl 
moiety that presumably occupies the Cys-Gly binding site. The peptidyl phosphonate inhibitors 
are highly useful as a ligand for X-ray structural analysis of GGT for defining hitherto 
unidentified Cys-Gly binding site to design specific inhibitors. 
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1. Introduction 
γ-Glutamyl transpeptidase (GGT, EC 2.3.2.2) is a heterodimeric enzymes found widely in 
organisms ranging from bacteria, plants to mammals. GGT catalyzes the cleavage of the 
γ-glutamyl amide bond of glutathione (γ-L-glutamyl-L-cysteinylglycine), its S-conjugates, 
glutamine and other γ-glutamylamides to transfer the γ-glutamyl group to water (hydrolysis) or 
amino acids and peptides (transpeptidation) by the ping-pong mechanism via a γ-glutamyl- 
enzyme ester intermediate (Scheme 1A).
1-4
 Mammalian GGT is bound to the external surface of 
cell membrane and is expressed in high concentrations in kidney tubules, biliary epithelium and 
brain capillaries.
2, 5
 GGT plays a central role in glutathione homeostasis as the sole enzyme 
capable of cleaving γ-glutamyl bond of glutathione in the initial step of glutathione metabolism; 
GGT hydrolyzes the extracellular glutathione in concert with other dipeptidases to provide cells 
with cysteine, the rate-limiting substrate for intracellular de novo synthesis of glutathione.
4-8
 
GGT is also involved in the metabolism of xenobiotics by cleaving the γ-glutamyl bond of 
glutathione-S-conjugates as the initial step for their degradation and excretion.
2
 Accordingly, the 










 have been suggested repeatedly. GGT is also implicated in 







 and pulmonary disease.
22
 Hence the serum GGT level has been used extensively as a 
diagnostic/prognostic marker of liver dysfunction, coronary heart diseases, Type 2 diabetes, 
stroke and atherosclerosis.
7, 21
 While GGT is recognized widely as an integral component of 
cellular antioxidative defense system,
7, 8, 13
 several lines of evidence have indicated that GGT 
promotes oxidative stress by producing Cys-Gly, a highly reactive thiol that generates reactive 
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oxygen species (ROS) via metal ion-catalyzed reduction of molecular oxygen.
23
 Therefore, GGT 
can also be recognized as a pro-oxidant enzyme that potentially promotes oxidative stress.
24-27
 
The seemingly contradictory dual aspects of GGT, along with a complicated glutathione 
metabolism,
28
 have made the physiological characterization of GGT rather complex. However, 
the implication of GGT in a number of pathological processes strongly suggests a causative role 
of this enzyme
7, 23, 25, 27
 rather than a simple result of cellular adaptation to oxidative stress.
7, 8
 
Therefore, GGT is an attractive pharmaceutical target for cancer chemotherapy and a vast array 
of physiological disorders involving oxidative stress and glutathione metabolism.
13, 15, 22
  
So far a number of GGT inhibitors have been reported,
4, 29
 but acivicin, 
L-(αS,5S)-α-amino-3-chloro-4,5-dihydro-5-isoxazole, a classical glutamine antimetabolite 
antibiotic produced by Streptomyces sviceus,
30
 has been used by far the most extensively for 
both in vitro and in vivo inhibition of GGT.
31-33
 Acivicin, however, is not selective for GGT and 
inhibits many glutamine-dependent biosynthetic enzymes to show potent cyto- and 
neurotoxicity.
34, 35
 The frequent use of acivicin as a GGT inhibitor, irrespective of its toxicity, is 
primarily due to the irreversible nature of its inhibition; acivicin reacts with the catalytic Thr 
residue of GGT to make a covalent adduct to inactivate the enzyme (Scheme 1B).
36, 37
 Therefore 
the important criteria for GGT inhibitors of practical use both in vitro and in vivo are (1) 
irreversible inhibition with no regain of enzyme activity until new enzymes are de novo 
synthesized and (2) high selectivity for GGT without inhibiting glutamine-hydrolyzing 
biosynthetic enzymes. In view of these criteria, we reported a series of phosphonate esters as 
active-site directed and transition-state analogue inhibitors of GGT.
38, 39
 The phosphonate esters 
react in a mechanism-based manner with the N-terminal Thr residue in the small subunit, the 
catalytic nucleophile of GGT,
40, 41
 to inactivate the enzyme completely. Among those inhibitors, 
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compound 1 (a mixture of four stereoisomers, see Section 2.5 and Table 1) closely mimicking 
the transition state 1 (TS-1) for glutathione hydrolysis, exhibited an exceptionally higher 
inhibitory activity (> 180 times) toward human GGT than the phosphonate with a simple 
methoxy group in place of the peptidyl chain.
39
 Interestingly, the E. coli enzyme did not show 
any extra sensitivity toward the phosphonate 1. This observation suggested that the presence of 
the peptidyl chain significantly improved the affinity of compound 1 to the active site of human 
GGT, thereby facilitating the formation of the enzyme-inhibitor covalent complex that is closely 
analogous to the putative transition state TS-1 (Scheme 1A, C). We reasoned therefore that 
human GGT, but not the E. coli enzyme, held a defined Cys-Gly binding site that could provide 
an extra, or in some cases, a major binding energy to enhance the inhibitory activity of the 
covalent-type phosphonate inhibitors. The characterization of the Cys-Gly binding site of GGT is 
also important in reducing the toxicity of inhibitors by avoiding accidental inhibition of the 
glutamine-hydrolyzing enzymes; the inhibitors that could exploit the binding energy effectively 
from the Cys-Gly binding site, like compound 1, should be bound tightly to the active site of 
GGT, but not to the active site of glutamine-hydrolyzing enzymes that are presumably devoid of 
the Cys-Gly binding site. 
Several X-ray crystal structures of bacterial GGTs have been reported,
36, 42-45
 but none of 
them were successful in identifying the Cys-Gly binding site. In contrast, the mammalian 
enzymes, whose natural substrate is glutathione and its S-conjugates, are expected to have a 
defined binding site for Cys-Gly. Very recently the X-ray crystal structure of human GGT was 
solved,
46
 presenting the first tertiary structure of eukaryotic GGT. However, the Cys-Gly binding 
site is still undefined by the X-ray crystal structure of human GGT in complex with glutamate, 
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suggesting that the structural identification of Cys-Gly biding site is very difficult without a 
minutely designed ligand that could incorporate a Cys-Gly moiety. 
Here we report the synthesis and evaluation of a series of glutathione-analogous peptidyl 
phosphorus esters 2a-g, 3 and 5 that incorporated a Cys-Gly moiety in a transition-state 
analogous scaffold (Fig. 1). The extent of mechanism-based inhibition depending on the 
structural differences in the peptidyl moiety has gained insights into the structural and 
stereochemical preferences of the putative Cys-Gly binding site of human and E. coli GGTs. 
Human GGT was highly selective for a mimic of L-form of an aliphatic amino acid such as 
L-2-aminobutyrate (a L-Cys mimic) and L-norleucine (a L-Met mimic) at the Cys binding site, 
whereas E. coli GGT significantly preferred an aromatic amino acid (L-Phe) at this site. Both 
enzymes required the C-terminal Gly for effective inhibition, suggesting that E. coli GGT, as 
well as the human enzyme, still retained some characters for binding dipeptides such as L-amino 
acyl (L-AA)-Gly. The transition-state mimicry and the phosphorus stereochemistry of these 
inhibitors successfully allowed access to the stereochemical course of the nucleophilic attack of 
the catalytic Thr residue on the γ-carbonyl of glutathione in the catalyzed reaction. 
 
2. Results and discussion 
2.1. Analogue design 
The synthesized phophonate diesters 2a-g and 3 contain the peptidyl side chains that mimic 
L-2-aminobutyrylglycine (L-Abu-Gly, 2a), glycylglycine (Gly-Gly, 2b), L-β-chloroalanylglycine 
(L-β-ClAla-Gly, 2c), L-β-iodoalanylglycine (L-β-IAla-Gly, 2d), L-phenylalanylglycine 
(L-Phe-Gly, 2e), L-norleucylglycine (L-Nle-Gly, 2f), D-norleucylglycine (D-Nle-Gly, 2g) and 
L-norleucine methyl ester (L-Nle-OMe, 3) (Fig. 1). The L-Abu-Gly moiety of 2a is a mimic of 
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L-Cys-Gly in glutathione with the assumption that a methyl is sterically analogous to SH. A 
halogen atom was introduced (chlorine and iodine for 2c and 2d, respectively) in the hope that 
the halogen atom also mimics the SH of the L-Cys residue. In view of L-Met as a preferred 
acceptor substrate of rat kidney GGT,
3, 47
 the norleucyl series 2f (L-Nle-Gly), 2g (D-Nle-Gly) and 
3 (L-Nle-OMe) were synthesized to mimic L-Met-Gly, D-Met-Gly and L-Met-OMe, respectively. 
The synthesis of a carboxy derivative of 3 was unsuccessful due to hydrolytic instability of the 
compound probably by intramolecular nucleophilic catalysis by the adjacent carboxy group.
48 
 
The phosphonate 4 carries a dipeptide mimic of L-Abu-Gly (same as 2a), but with a poor 
leaving group (OMe) in place of phenoxy attached to the phosphorus. Compound 5 is a 
phosphinate version of 2b with a Gly-Gly side chain (see Section 2.4).  
 
2.2. Synthesis of phosphonate diesters 2a-g, 3 and 4 
The synthesis of the peptidyl moieties is shown in Scheme 2. The preparation of the peptidyl 
phosphorus esters required a series of α-hydroxy acids with defined stereochemistry that mimic 
the L- or D-amino acid at the Cys moiety of glutathione. The chiral α-hydroxy acids 7a, e-g were 
prepared from the corresponding L- or D-amino acids (6a, e-g, respectively) with retention of 
configuration by diazotization followed by hydrolysis.
49
 The optical rotations of 7e-g were in 
good agreement with the reported values.
49
 The (R)-3-chloro-2-hydroxypropionic acid (7c) was 
prepared from commercial (R)-3-chloropropane-1,2-diol (10) by selective oxidation of the 
primary hydroxy with nitric acid.
50, 51
 Each of the chiral α-hydroxycarboxylic acids 7a, c, e-g and 
commercial grade glycolic acid (7b) was condensed with glycine benzyl ester monotosylate (8) 
by the conventional peptide coupling method to give the α-hydroxycarboxamides 9a-c, e-g, 
respectively (Scheme 2). Iodine atom was introduced by treating the chloride 9c with sodium 
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iodide in refluxing acetonitrile to give 9d in 45% yield. Treatment of 7f with thionyl chloride in 
methanol gave methyl (S)-2-hydroxyhexanoate (11) in 84% yield. 
The peptidyl phosphonate diesters 2a-g, 3 and 4 were synthesized as shown in Scheme 3. 
The hetero-diesters of phosphonic acid was prepared from the phosphonyl dichloride by stepwise 
reaction with phenol (a leaving group) and α-hydroxycarboxamides 9a-c, e-g (a peptidyl side 
chain) according to our previously reported procedure.
39
 Thus, the fully protected phosphonic 
acid 12 (racemic form)
39
 was converted to the phosphonyl dichloride 13. Selective substitution 
of a single chlorine atom of 13 was achieved by pre-mixing 13 and phenol, followed by the 
addition of Et3N at low temperature (-65ºC) as a catalyst.
52
 The resulting phosphonyl 
monochloro monophenyl ester was then allowed to react with the α-hydroxycarboxamides 9a-g 
or the α-hydroxyester 11 to give the phosphonyl hetero-diesters 14a-g and 15, respectively. This 
procedure, however, usually accompanied the formation of the homo-diphenyl and 
homo-bis-peptidyl esters of 12 regardless of careful operations, and gave the desired 
hetero-diesters 14a-g and 15 in moderate yields after careful chromatographic separation. The 
results under several reaction conditions indicated that the initial reaction with phenol should be 
conducted at sufficiently low temperature by initiating the reaction with NEt3 for substitution of 
a single chlorine atom of 13. However, the initial ratio of the intermediate monochloro 
monophenyl ester (δP 39.6) was not in agreement in several cases with the product ratio of the 
hetero-diesters, and the formation of the homo-bis-peptidyl esters was observed even in the 
reactions where complete consumption of the dichloride 13 (δP 49.2) was confirmed by 
31
P NMR. 
This observation suggested that the intermediate monochloro monophenyl ester (δP 39.6) reacted 
with the second peptidyl alcohol by substitution with phenol, as well as with chlorine. It is 
noteworthy that the formation of homo-bis-peptidyl and diphenyl esters was not suppressed by 
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reversing the order of reaction of 13 with the α-hydroxycarboxamides and phenol (data not 
shown). Reaction of the dichloride 13 with methanol and 9a by the same procedure afforded the 
peptidyl methyl phosphonate 16. At this stage, the compounds 14a-g, 15 and 16 were obtained as 
a mixture of equal amounts of four diastereoisomers (for 14a, c-g, 15 and 16) or four 
stereoisomers (two sets of enantiomers) (for 14b) with respect to the stereogenic centers at the 
α-carbon of the glutamate moiety and the phosphorous atom. No attempts were successful in 
separating the diastereoisomers at this stage (see Section 2.2). Removal of the benzyl protecting 
groups by catalytic hydrogenation gave the desired phosphonates 2a-c, 2e-g, 3 and 4. 
Interestingly, the iodine analogue 14d did not react under the conventional hydrogenolysis 
conditions (H2 gas /10% Pd-C). Hence the deprotection of 14d was achieved under the 
nucleophilic C-O bond cleavage conditions using anisole/aluminum chloride to give 2d in 22% 
yield. 
 
2.3. Separation of diastereoisomers with respect to chiral phosphorus by MPLC  
Starting with racemic 2-amino-4-phosphonobutanoic acid,
53, 54
 the reaction with chiral 
α-hydroxycarboxamides 9a, c-g and α-hydroxyester 11 gave the corresponding peptidyl 
phosphonate diesters 2a, c-g, 3 and 4 as a mixture of four diastereoisomers with respect to the 
newly formed chiral phosphorus and the original chiral α-carbon of the glutamate moiety. In 
compound 2b, the absence of a chiral carbon in the peptidyl chain gives a mixture of four 
stereoisomers (two sets of enantiomers) with respect to the same stereogenic centers. 
We found in the purification step that two sets of diastereoisomers were separated for 
compounds 2a, c-g, 3 and 4 by reversed phase medium pressure liquid chromatography (MPLC) 
(Fig. 2). We collected each peak separately and designated peak A (slow-eluting) and peak B 
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(fast-eluting). In contrast, no chromatographic separation of diastereoisomers was observed with 
compound 2b. This chromatographic behavior, in view of the distal stereogenic center at the 
α-carbon of the glutamate moiety, suggested that the separated diastereoisomers (peak A and B) 
of 2a, 2c-g, 3 and 4 were related to the difference in the stereochemistry at the chiral 
phosphorous (SP* or RP*) relative to the fixed stereogenic center at the adjacent peptidyl moiety.  
It seems that the stereogenic center (Lα or Dα) at the α-carbon of the glutamate moiety is not close 
enough to the chiral phosphorous and/or the peptidyl -carbon to effect diastereoisomeric 
differences in the MPLC behavior. Hence each peak A and B is composed of a mixture of two 
diastereoisomers with respect to the distal chiral α-carbon (Lα or Dα) of the glutamate moiety. 
This view was supported by the spectroscopic data for peak A and B; each gave a single peak or 
very close two peaks (equal height) in 
31
P NMR and an apparently single set of peaks in 
1
H 
NMR.  We therefore concluded that the separated diastereoisomeric pairs (peak A and B) of 2a, 
2c-g, 3 and 4 were related to the chiral phosphorus and that the diastereoisomers belonging to 
peak A had the same stereochemistry at the chiral phosphorus (SP*, see below), but it was 
opposite to that of the diastereoisomers in peak B (RP*). Note that each peak A and B is still 
composed of equal amounts of two diastereoisomers with opposite stereochemistry (Lα or Dα) at 
the chiral α-carbon of the glutamyl moiety, but they behaved like enantiomers due to the distance 
of this chiral center. For the same reason, the diastereoisomers of compound 2b behaved like 
enantiomers and were not separated by MPLC to give a mixture of four stereoisomers (two sets 
of enantiomers) with equal amounts. 
For the phosphonate diesters 2a, c-g and 3, the slow-eluting peak A invariably showed high 
inhibitory activities, whereas the fast-eluting peak B exhibited little or no activity (see Sections 
2.5 and 2.6). For this reason, we used the inhibitory activities of peak A (a mixture of two 
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diastereoisomers) in the following discussion. For compound 2b, the inhibitory activity was 
evaluated for a mixture of four stereoisomers. The absolute configuration of the chiral 
phosphorus was not determined experimentally, but was assigned tentatively as SP* and RP* for 
the isomers in peak A and peak B, respectively, from our preliminary results on the X-ray crystal 
structural analysis of E. coli GGT in complex with 2a-A (Supplemental Fig. S1, see Section 2.5 
for details). 
 
2.4. Synthesis of phosphinate ester 5 
The phosphinate 5 was synthesized as shown in Scheme 4. The protected L-glutamic acid 17 
was converted to the L-vinylglycine derivative 18 by the reported procedure.
55
 Phosphorus atom 
was introduced by triethylborane-catalyzed radical addition of ammonium hypophosphite
56
 to 
give the hydrophosphinic acid 19 in good yield. The crude product was treated as such with 
N,O-bis(trimethylsilyl)acetamide (BSA), and the resulting trivalent trimethylsiyl (TMS) 
phosphite was allowed to react by conjugate addition with t-butyl acrylate to give the 
(S)-phosphinic acid derivative 20 quantitatively. We initially tried to react with ethacrylamide 21 
to synthesize directly the corresponding phosphinate derivative with a DL-Abu-Gly analogous 
peptidyl chain, but the reaction did not work with less reactive Michael acceptor ethacrylamide 
21. Hence we used the sequential three-step reaction involving the Michael addition to tert-butyl 
acrylate to give 20, followed by deprotection of the tert-butyl ester and condensation with the 
glycine benzyl ester monotosylate (8) to give the full-length phosphinic acid 23 in a total yield of 
50% from 18. Treatment of 23 with oxalyl chloride followed by reaction with phenol gave the 
phosphinate ester 24 in 55% yield. Removal of the benzyl protecting groups by catalytic 
hydrogenolysis afforded the desired phosphinate ester 5 with a Gly-Gly mimic peptidyl chain. 
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Compound 5, synthesized from L-vinylglycine derivative 18, was composed of equal amounts of 
two diastereoisomers with respect to the chiral phosphorus, but, as seen for compound 2b, the 
diastereoisomers of 5 behaved like enantiomers and were not separable by reversed phase MPLC 
due to the absence of a fixed stereogenic center at the -carbon of the adjacent peptidyl moiety. 
Hence we used compound 5 for the following enzyme assays as a 1:1 mixture of two 
diastereoisomers with opposite stereochemistry at the chiral phosphorus. Compound 5 is the 
phosphinate version of compound 2b, but it should be noted that compound 2b, synthesized from 
racemic 2-amino-4-phosphonobutanoic acid, was a mixture of four stereoisomers (two sets of 
enantiomers) with respect to the stereogenic centers on the phosphorus (RP* or SP*) and the 
distal α-carbon (Lα or Dα) at the glutamyl moiety, whereas compound 5 was a mixture of two 
diastereoisomers (Lα, RP*) and (Lα, SP*). For clarity, the stereoisomeric composition and the 
configuration of each isomer for compounds 1, 2a-g, 3, 4 and 5 are summarized in Table 1. The 
stereoisomeric composition of compound 1
39
 will be discussed in Section 2.5. The 
stereochemistry of peak A and B of compound 2g is worth noting. This compound was 
synthesized from (R)-α-hydroxycarboxamide 9g, a mimic of D-Nle-Gly, and its stereochemistry 
(Dα’) at the α-carbon of the peptidyl chain adjacent to the phosphorus was opposite to that of 
compound 2f (Lα’) derived from (S)-α-hydroxycarboxamide 9f. Therefore, the chromatographic 
behavior of the (RP*, Dα’) isomer of 2g on MPLC should be similar to that of the (SP*, Lα’) 
isomer of 2f, because, due to the distance of the remaining stereogenic center (Lα or Dα) at the 
α-carbon of the glutamate moiety, these two sets of diastereoisomers are pseudo-enantiomorphic 
and hence are expected to behave like enantiomers on MPLC. We therefore assigned the 
stereochemistry at the chiral phosphorus in peak A (slow-eluting) and peak B (fast-eluting) as 
RP* and SP*, respectively, for compound 2g. Thus, the peak A of 2g was composed of two 
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diastereoisomers (Lα, RP*, Dα’) and (Dα, RP*, Dα’), and peak B was a mixture of two 
diastereoisomers (Lα, SP*, Dα’) and (Dα, SP*, Dα’). The diastereoisomers contained in each peak A 
and B of 2g were pseudo-enantiomorphic and were not separable by MPLC. 
 
2.5. Inhibitory activities toward human GGT 
The inhibitory activities of the phosphorus esters 2a-g, 3, 4 and 5 were evaluated against 
human and E. coli GGTs according to our previous method.
38, 39
 Enzyme activity was measured 
using 7-(γ-L-glutamylamino)-4-methylcoumarin (γ-Glu-AMC)57 as substrate, and release of 
7-amino-4-methylcoumarin (AMC) was detected fluorimetrically and continuously as the 
progress of enzyme reactions. We employed a hydrolytic condition without using a γ-glutamyl 
acceptor substrate such as Gly-Gly,
3
 because a high concentration of Gly-Gly may compete with 
the peptidyl moiety of the phosphorus esters 2a-g, 3, 4 and 5 for the enzyme Cys-Gly binding 
site, thereby complicating the inhibition kinetics. To suppress the possible auto-transpeptidation,
3, 
4
 the reaction was conducted under an acidic condition (pH 5.5), where the transpeptidation 
activity is relatively low,
58
 and by using lower concentrations of substrate (4.0 and 0.2 M of 
-Glu-AMC for human and E. coli GGT, respectively), which correspond to 1/3 and 1 Km value 
for human and E. coli GGT, respectively. 
The phosphonate diesters 2a-f (peak A, except 2b) with a good leaving group (phenoxide) 
served as potent and irreversible inhibitors of human GGT. Typical progress curves for the 
reaction catalyzed by human GGT in the presence of varying concentrations of compound 2a-A 
are shown in Fig. 3A. The inhibitory activities were evaluated by calculating the second-order 
rate constant (kon) for enzyme inactivation, assuming a bimolecular reaction of enzyme and 
inhibitor to form a covalent enzyme-inhibitor covalent complex (E-I) (see Section 2.7, Fig. 5). 
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Thus, the time-dependent inhibition curves were fit to the first-order rate equation (1) (see 
Section 4.3.2) to determine the observed pseudo-first-order rate constant for enzyme inactivation 
(kobs) at each inhibitor concentration. A plot of kobs against inhibitor concentration gave a straight 
line without saturation until the highest inhibitor concentration (data not shown), indicating that 
the reversible formation of EI complex was kinetically incompetent under the reaction conditions 
employed. Hence the kon values, the second-order rate constants for enzyme inactivation, were 
calculated from the slope on the assumption that the inhibitor was competitive with the substrate 
[equation (2) in Section 4.3.2]. The results are summarized in Table 2. Among the inhibitors 










) measured under the same reaction conditions, indicated that 2a was an extremely potent 
irreversible inhibitor of human GGT that inactivated the enzyme more than 360 times as quickly 
as acivicin. This observation was in accordance with our initial expectations that the L-Abu-Gly 
peptidyl chain in 2a was highly analogous to the L-Cys-Gly moiety in glutathione to favor its 
binding to the active site of human GGT, to facilitate covalent bond formation with the catalytic 
Thr residue and to give the adduct that was a mimic of the putative transition state (TS-1) for the 
catalyzed reaction with glutathione (Scheme 1). A methyl as a good mimic of SH was also 
shown in the sulfoximine-based transition-state analogue inhibitors of γ-glutamylcysteine 
synthetase, the first and the rate-limiting enzyme in glutathione biosynthesis.
59
 We previously 
reported that the parent compound 1, a mixture of stereoisomers synthesized from racemic 






 Assuming that the 
inhibition of human GGT is highly dependent on the stereochemistry at the chiral phosphorus, 
which will be discussed later, the inhibitory activity is then proportional to the stereoisomeric 
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) was about a half that of 2a that was a mixture 
of two diastereoisomers, suggesting that the previously synthesized 1 was a mixture of four 
stereoisomers (Table 1) rather than eight, probably due to the isolation of peak A solely during 
the chromatographic purification by MPLC. Therefore compound 1 was composed of (Lα, SP*, 
Lα’), (Lα, RP*, Dα’), (Dα, SP*, Lα’) and (Dα, RP*, Dα’) as shown in Table 1. 
Removal of the ethyl group from the L-Abu-Gly peptidyl chain significantly decreased the 
inhibitory activity (2b). It should be noted that 2b was racemic at both the chiral phosphorus and 
the α-carbon at the distal glutamate moiety, and was composed of equal amounts of four 
stereoisomers (Table 1). With an assumption that the only SP* isomer is active, the observed kon 
value of 2b (a mixture of four) should be doubled when compared to that of 2a (a mixture of 




) was still 61% of the kon value of 2a, indicating a 
significant contribution of the ethyl group to the enzyme inhibition. Interestingly, the 
introduction of a chloromethyl (2c) or iodomethyl group (2d) caused almost no difference in the 
inhibitory activity as compared to 2b. We initially anticipated that a chlorine and iodine atoms 




















 However, the introduction of a chloromethyl (2c) and iodomethyl (2c) had almost 
no impact on the activity of the inhibitors, whereas the introduction of an ethyl (2a) (CH3 as SH 
mimic) increased the activity by 63% as compared to 2b. This observation might be due to a 
little too small and large in size of chlorine and iodine atom, respectively, for a SH mimic, with a 
methyl group in between being a good compromise. In this sense, a bromine atom with a van der 




 might be a reasonably good mimic of SH. Human GGT thus 
strictly recognized the size of the substituent attached to the β-carbon of the side chain of the Cys 
 17 
moiety and that a SH group or its equivalent in size seems preferable at this site. This is 
highlighted by a significantly low activity of 2e with a side chain mimicking L-Phe-Gly. This 
compound with a bulky phenyl group attached to the β-carbon was found to be an extremely 
weak inhibitor of human GGT (only 3% of compound 2a). This result is consistent with the 
acceptor substrate specificity of rat kidney GGT, where L-Phe-Gly was a significantly poor 
dipeptide substrate.
3
 It is noteworthy, however, that elongation of the side chain of 2a by two 
methylene units did not severely affect the inhibitory activity; compound 2f with a 




 that was 
44% of that of 2a. This result, combined with the moderate activities of 2c and 2d, and 
remarkably low activity of 2e, indicated that the γ-position of the side chain that is usually 
occupied by the SH of Cys was strictly recognized by the enzyme, whereas the group beyond 
this position might be forced out of the active site, thereby escaping from the steric constraint 
and recognition by the enzyme. Furthermore, the stereochemistry at the α-carbon of the Cys 
moiety and the presence of the C-terminal Gly had a significant impact on the inhibition activity: 
the inversion of stereochemistry at the α-carbon of the Cys moiety (2g) or removal of the 
C-terminal Gly (3) resulted in a complete loss of inhibitory activity (Table 2). Thus, human GGT 
was inactivated strongly only by the phosphonate with a peptidyl side chain that is structurally 
and stereochemically equivalent to L-Cys-Gly. This is consistent with the observation that GGT 
accepts only L-amino acids or peptides as γ-glutamyl acceptor substrate3 and is in good 
agreement with the putative substrate recognition and inhibition mechanisms proposed by us that 
human GGT strongly recognizes the negative charge at the C-terminal Gly of glutathione.
39
 
We found that peak A of compounds 2a, c-f was invariably active, whereas peak B was 
completely inactive towards human GGT. These results indicated that human GGT strictly 
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recognized the stereochemistry at phosphorus; the isomers A (tentatively assigned as SP*) was 
exclusively accommodated and/or reacted with the active-site Thr residue, leading to enzyme 
inactivation. The assignment of the configuration at phosphorus was derived from our 
preliminary results on the X-ray crystallographic analysis of E. coli GGT in complex with 2a-A, 
in which SP configuration was observed at the chiral phosphorus that was covalently bound to the 
Oγ atom of Thr391 (Supplemental Fig. S1). Since both human and E. coli GGTs were 
inactivated by the same isomers (peak A), the stereochemical preference of both enzymes for the 
chiral phosphorus is the same (see Section 2.6). We therefore tentatively assigned the original 
stereochemistry at phosphorus of 2a-A (peak A) as SP* by assuming the in-line substitution at 
phosphorus with inversion of configuration [Note that the phosphorus stereochemical 
assignments for the phenyl phosphonate (before reaction) and the enzyme-inhibitor complex 
(after reaction) are the same (SP*) due to the sequence rule for the ligands around the phosphorus, 
irrespective of the inversion of configuration].  
Table 2 also highlights the strict stereochemical recognition by human GGT. Neither peak A 
nor peak B of the phosphonate 2g was inhibitory toward human GGT, indicating that none of the 
four stereoisomers of 2g (Table 1) was acceptable by the enzyme irrespective of the 
configuration at phosphorus. This was due to the D-configuration at the α-carbon of the Cys 
moiety of 2g. Conversely, peak B of compound 2f was totally inactive irrespective of the 
L-configuration at the α-carbon of the Cys moiety, because the isomers in peak B had the RP* 
configuration at phosphorus. Therefore human GGT is highly selective for SP*-phosphorus and 
L-α-carbon at the Cys moiety in the peptidyl chain, and does not accept any other stereoisomers. 
Since the phosphonate inhibitors 2a, c-f are a good mimic of the putative transition state 
(TS-1) for the catalyzed reaction of glutathione (Scheme 1), the stereochemistry at phosphorus is 
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closely related to the stereochemical outcome of the catalyzed reaction with glutathione. This is 
illustrated in Fig. 4. In the active site of human GGT, the isomer(s) 2f-A with SP* configuration 
at phosphorus is accommodated and reacted with the catalytic Thr residue (γOH) that approaches 
the phosphorus opposite to the phenoxy leaving group and then substitutes the phenoxy in line 
with inversion of configuration at phosphorus, thus making an enzyme-inhibitor covalent 
complex with SP* configuration (panel A to B). In contrast, the isomer(s) 2f-B with RP* 
configuration at phosphorus is not reactive probably because of the unfavorable configuration for 
accommodation in the enzyme active site and/or for in-line substitution by the catalytic Thr 
residue. If this stereochemistry holds for the catalyzed reaction, then the nucleophilic attack of 
the Thr γOH occurs on the Si-face (above the plane) of the γ-carbonyl of glutathione to make a 
tetrahedral oxyanion with S configuration (panel C to D). This stereochemical course seems 
quite reasonable from a steric point of view: the catalytic Thr γO approaches the phosphorus (for 
2a-A) or the γ-carbonyl (for glutathione) from the less-hindered side that is opposite to the L-Cys 
side chain and makes a tetrahedral (SP*)-adduct (for 2a-A) or (S)-oxyanion (for glutathione) in 
which the O-Thr is located above the plane, while the side chain of the L-Cys moiety occupies 
below (Figure 4, B and D). Since the phosphorus stereochemistry of the active inhibitor is 
assigned tentatively as SP*, we cannot rule out the possibility that all the stereochemistry shown 
in Fig. 4 would be reversed: the active-site Thr γOH attacks from the bottom side on the RP* 
phosphorus of 2a-A to make a (RP*)-adduct, which corresponds to the attack of Thr γOH on the 
Re-face (below) of the γ-carbonyl of glutathione to make a (R)-tetrahedral intermediate. This 
mode of reaction, however, appears unfavorable from a stereochemical point of view, because 
Thr γOH attacks the phosphorus or the γ-carbonyl from the same side of the Cys side chain. The 
defined stereochemical assignments have to await the X-ray structural analysis of human GGT in 
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complex with 2a-A. 
In this model, we also proposed the mode of recognition of the Cys-Gly moiety; human 
GGT has a specific binding site for the Cys moiety to recognize strictly its stereochemistry (Lα’) 
and the size of its side chain up until the sulfur atom probably by a narrow cavity around this 
part, but no recognition is inferred for any group beyond that position. This mode of recognition 
of the Cys residue is reasonable for GGT that accepts a variety of glutathione-S-conjugates as 
substrates. This is illustrated by the reaction of GGT with 2f-A (Fig. 4, A and B) where the L-Nle 
residue is bound or recognized by the enzyme up until the γ-carbon. No stereoisomers with 
D-configuration at the Cys moiety are permitted for binding and reaction with the enzyme active 
site. In addition, the C-terminal carboxy group of the Gly moiety is strictly recognized by an 
electrostatic interaction with a positively charged active-site residue.
39
 The active-site residue 
that recognizes the negative charge of the acceptor substrate in the transpeptidation reaction was 
recently reported to be Lys562.
61
 Since the peptidyl chain of the present phosphonate inhibitors 
is equivalent to the acceptor substrate and the Cys-Gly moiety of glutathione, this residue is 
probably responsible for the recognition of the C-terminal negative charge in the present peptidyl 
phosphonate inhibitors, as well as that of the C-terminal Gly of the substrate glutathione. 
A good leaving group such as phenoxy attached to the phosphorus was absolutely necessary 
for enzyme inactivation. The methyl ester 4 was totally inactive toward the enzyme, irrespective 
of the presence of SP* phosphorus and L-Abu-Gly peptidyl chain. This is naturally understood by 
the inactivation mechanism; the electrophilic phosphorus with a good leaving group reacted with 
the active-site Thr γOH to phosphonylate and inactivate the enzyme (see Section 2.7 and Fig. 5). 
The structure of 4 is highly analogous to glutathione, but the enzyme activity was not affected 
appreciably even in the presence of a high concentration (1 mM) of compound 4 (Supplementary, 
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Fig. S2). This result indicated that, contrary to our initial expectations, the affinity of the 
phosphonate 4 with the enzyme active site was substantially low. This is probably due to the 
sp
3
-hybridized tetrahedral phosphorus carrying a methoxy group that is substantially different in 
size and shape from the sp
2
-hybridized γ-carboxamide of glutathione and from the tetrahedral 
oxyanion. If this is the case, the initial binding of 2a is expected to be unfavorable, although the 
enzyme was inactivated by the phosphonate rather fast. In fact, the Ki value for a related 
phosphonate inhibitor was 0.17 mM.
39
 
The phosphinate inhibitor 5, a closely related analogue of the phosphonate 2b, showed a 




) toward human GGT. The phosphinate 5 was a 
mixture of two diastereoisomers, while the phosphonate 2b was four. Hence the net inhibitory 
activity of 5 was even worse and no more than 1.6% of that of 2b. Despite its low activity, 
compound 5 caused a time-dependent inhibition of human GGT, giving a series of concave 
upward progress curves in the inhibition assay (Supplementary Fig. S3). This is indicative of 
covalent modification of the enzyme active site by the phosphinate 5, but the reaction was 
substantially slow. The significantly lower activity of phosphinate 5 as compared to the 
phosphonate counterpart 2b was totally unexpected from our initial expectations that the 
phosphinate ester 5 would be more reactive than the phosphonate ester 2b due to the absence of 
the ground-state resonance stabilization by pπ-dπ conjugation with the oxygen and phosphorus.
62
 
We therefore speculated that, in the reaction of the active-site Thr γOH and the phosphorus 
inhibitors, the inductive (-I) effect by an electronegative oxygen had a larger impact on the 
reactivity than the pπ-dπ conjugation resonance effect. We reported previously that the reaction of 
GGT with phosphonate-diester based inhibitors proceeded via a dissociative transition state in 
which a substantial P-O bond cleavage is inferred.
39
 In this transition state, the positively 
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charged phosphorus atom might be stabilized effectively by an electron-donating resonance 
effect of the oxygen to facilitate the reaction. 
 
2.6. Inhibitory activities toward E. coli GGT 
Under the same reaction conditions, the activities of 2a-f, 3, 4 and 5 (peak A, except 2b) 
were evaluated for the inhibition of E. coli GGT. The peak A of the phosphonate diesters 2a, c-f 
and 3 invariably caused time-dependent inhibition of E. coli GGT (Fig. 3B), whereas peak B was 
uniformly inactive.  
In sharp contrast to human GGT, the E. coli enzyme was strongly inactivated by 2e with a 
L-Phe-Gly analogous peptidyl chain that was more than 3.5 times as active as 2a. This is 
consistent with the fact that aromatic L-amino acids such as L-Phe, L-His and L-DOPA serve as a 
good acceptor substrate of E. coli GGT in transpeptidation.
63
 Inhibitors 2a-d and 2f inactivated E. 
coli GGT with kon values ranging from 50.7 to 188, but no clear relationship was observed 
between their inhibition potency and the structure of the side chains at the Cys moiety. L-Met 
was reported to be nearly twice as good as L-Phe as an acceptor substrate,
63
 but the inhibitor 2f 




) was only13% as active as 2e. A 
hydrogen bond involving a sulfur atom
64
 might be playing a role in the recognition of Met as 
noted for capD, a GGT family enzyme from Bacillus anthracis.
61
 
In contrast to human GGT, the E. coli enzyme was inactivated slowly by 2g with a 
D-Nle-Gly peptidyl chain, suggesting that the E. coli enzyme was not highly selective for the 
L-configuration at the α-carbon of the Cys-Gly peptidyl chain. With respect to the chiral 
phosphorus, the E. coli enzyme was not highly selective, either; E. coli GGT was inactivated 
slowly by 2f-B and 2g-A both with RP* phosphorus, whereas these compounds were totally 
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inactive toward human GGT. It appears therefore that E. coli GGT does not particularly prefer 
L-Cys or its equivalent at the Cys-Gly binding site, and that the enzyme does not strictly 
recognize the stereochemistry at chiral phosphorus and the α-carbon of the Cys moiety. The 
properties of E. coli GGT suggest that the natural and preferred substrates of E. coli GGT are not 
glutathione or its S-conjugates, but other exogenous γ-glutamyl amides that can be processed by 
this enzyme as a nutrition source.
65
 According to the substrate preference of the E. coli enzyme, 
such γ-glutamyl peptides presumably contain an aromatic moiety (L-Phe, Tyr, Trp and so on) or 
its equivalent at the peptide moiety. The identification of those γ-glutamyl peptides is intriguing 
in terms of natural occurrence of novel γ-glutamyl compounds.  
The relatively non-selective nature of the E. coli enzyme is supported by the inhibitory 
activity of 3 that is devoid of the C-terminal Gly moiety. This compound was totally inactive 




) was observed with E. coli 
GGT. Compound 3, however, was substantially less active (ca. 17%) than 2f, implying that the 
C-terminal Gly still contributed noticeably to the affinity of the inhibitor in the active site. This 
result is indicative of a putative Cys-Gly binding site still conserved in E. coli GGT. Several 
X-ray crystal structural analyses have been reported for bacterial GGTs,
42-45, 66
 but none of them 
was successful in identifying the Cys-Gly binding site. In the crystal structures of E. coli GGT, 
the detection of intact glutathione failed even after the soaking of the enzyme crystals into a 
glutathione solution for a short period followed by rapid freezing.
42
 An attempt to detect the 
structure of intact glutathione in complex with Helicobactor pylori GGT was made by using a 
catalytically inactive mutant enzyme (Thr380Ala), but the Cys-Gly portion of the enzyme-bound 
glutathione was invisible by X-ray structural analysis due to considerable mobility beyond the 
γ-glutamyl group.44 These results suggested that no defined Cys-Gly binding site was present in 
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bacterial GGTs. However, the properties of E. coli GGT as probed by the present phosphonate 
inhibitors cogently suggested the presence of a putative or remaining characters of the binding 
site for the Cys-Gly moiety that accommodates the amino acyl (AA)-Gly moiety of 
γ-glutamylamide substrates or an acceptor substrate AA-Gly. In this regard, we could exploit the 
differences in the structural and stereochemical preferences of enzymes in the Cys-Gly binding 
site for generating selective inhibitors; a phosphonate diester, for example, with a D-AA-Gly or 
L-AA side chain that incorporates an appropriate aromatic substituent at the AA moiety would be 
selective for E. coli GGT without inhibiting the human enzyme. 
We previously reported the inhibitory activities of a series of simple phosphonate diesters 
with a substituted phenol as a leaving group.
39
 The E. coli enzyme was uniformly two orders of 
magnitude more sensitive to those inhibitors than human GGT. It is worth noting that in the 
present phosphonate inhibitors 2a-f with a peptidyl side chain, the inhibitory activities (kon 
values) toward E. coli GGT were not so much different from those toward the human enzyme 
(Table 2). These observations can be explained by the difference in the extent of recognition of 
the Cys-Gly moiety by the enzymes; human GGT is highly selective for the Cys-Gly moiety of 
inhibitors and is strongly inhibited only by the inhibitors with an appropriate peptidyl chain or its 
equivalent that fits the defined Cys-Gly binding site, whereas the E. coli enzyme is relatively 
unselective for the Cys-Gly moiety and is inhibited generally by simple phosphonates without 
the Cys-Gly peptidyl moiety. Hence the phosphonate diesters without an appropriate Cys-Gly 
mimic peptidyl chain are rather weak inhibitors of human GGT, but can be highly inhibitory 
toward the E. coli enzyme. The present peptidyl phosphonates 2a-f have the Cys-Gly mimicking 
peptidyl chain and hence are potent inhibitors of human GGT as well as the E. coli enzyme, if 
other requirements such as stereochemistry at the phosphorus and the side chain of the peptidyl 
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moiety are met. This view is consistent with the extremely weak inhibition of human GGT by 




) that lacks the Cys-Gly moiety, whereas the E. coli enzyme is highly 






 In this regard, the recently reported 
inhibitor OU749 and its analogues by Hanigan et al. bound to the acceptor substrate binding site 
can be an attractive option for selective inhibition of mammalian GGTs,
67-69
 but their reversible 
nature with micro-molar Ki values might be insufficient for complete elimination of GGT 
activities for a certain period of time in vitro and in vivo as was observed with acivicin.  
The phosphonate 4 with a poor leaving group and the phosphinate 5 did not inhibit E. coli 
GGT at all. Since the phosphinate 5 was weakly inhibitory toward human GGT, it stands out as 
the sole compound that inhibited human GGT selectively among the phosphorus ester-based 
inhibitors. The structure of 5 might be a good template for designing novel inhibitors selective 
for human GGT. 
 
2.7. Mass spectroscopic analysis of E. coli GGT in complex with inhibitor 
The structural defining of the Cys-Gly binding site of human GGT is one of the most 
challenging, but the most rewarding subjects in the studies on GGT. Directing towards this goal, 
the peptidyl phosphonate inhibitors 2a-f was designed also for use as a ligand for X-ray 
structural analysis of human GGT in view of the enzyme-inhibitor adduct that mimics the 
putative transition state (TS-1) for glutathione degradation (Scheme 1). For this purpose, the 
Cys-Gly mimicking peptidyl chain has to remain bound to the phosphorus after the reaction with 
the enzyme active site. This was confirmed by an ion-spray mass spectroscopy of E. coli GGT 
inactivated by compound 2a-A. We used E. coli GGT rather than the human enzyme, because 
highly and heterologously glycosylated human GGT would make the mass analysis very 
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complex. E. coli GGT was treated with 2a-A under varying conditions, and the small subunit 
from each experiment was separated by HPLC.
70
 The isolated small subunit (GGTS, ca. 20,000 
Da) was analyzed by electrospray ionization mass spectroscopy (ESI-MS) according to our 
previous method for detecting the catalytic residue (Thr391 in GGTS) of E. coli GGT.
40
 The 
untreated E. coli GGT was also processed in the same manner as reference. The results are 
shown in Fig. 5. The GGTS from the untreated enzyme gave a peak at m/z 20,014 (Fig. 5A) that 
corresponds to the expected molecular weight (20,010) of the unmodified small subunit 
calculated from its amino acid sequence.
70
 The small subunit obtained from the enzyme treated 
under a weak reaction condition (1.7 mM 2a-A, 20 min) gave two peaks at m/z 20,015.5 and 
20,323 (Fig. 5B). Finally, the small subunit from the enzyme with a stronger treatment (4 mM 
2a-A, 3 h) gave a single peak at m/z 20,323 (Fig. 5C). The mass difference (307.5) between the 
two peaks corresponded well to the calculated mass (308) of the inhibitor that is bound 
covalently to the catalytic Thr Oγ through a P-O bond with concomitant loss of the phenoxy 
group as shown in Scheme 1C. These results clearly indicated that the inhibitor 2a-A reacted 
with the active site of the enzyme to leave the Cys-Gly mimicking peptidyl moiety bound to the 
active site of GGT. Therefore the peptidyl phosphonate inhibitors 2a-f are highly promising as a 
ligand for X-ray structural analysis of GGT for defining the Cys-Gly binding site. 
 
3. Conclusions 
In this study, we designed and synthesized an array of novel peptidyl phosphorus esters as 
potent mechanism-based inhibitors of human and E. coli GGTs. The most active compound 2a 
with a L-Abu-Gly analogous peptidyl chain was more than 700 times as active as acivicin toward 
human GGT, if the stereoisomeric composition is considered. As a close mimic of the transition 
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state (TS-1) for glutathione degradation, the peptidyl phosphorus esters served as a good 
chemical probe to define hitherto unidentified Cys-Gly binding site of mammalian and bacterial 
GGTs. So far the substrate specificity of GGT for the Cys-Gly binding site have been estimated 
by using γ-glutamyl acceptor substrates3 with the assumption that the acceptor substrates 
AA-Gly bind to the same site as the Cys-Gly moiety of the γ-glutamyl donor substrates 
(glutathione). However, the approximation of substrate specificity by acceptor substrates might 
be misleading, because the apparent activity is significantly dependent on the extent of 
deprotonation or the pKa of the amino group of the dipeptidyl acceptor substrates (AA-Gly).
58
 In 
this regard, the phosphonate esters with a peptidyl side chain in the present study precisely 
reflect the properties of the Cys-Gly binding site; human GGT has a specific binding site for 
Cys-Gly to recognize strictly its stereochemistry (L) and the size of its side chain up until the 
sulfur atom, but no recognition is expected for any group beyond the sulfur (γ-position). This 
mode of substrate recognition seems quite reasonable from the proposed physiological function 
of mammalian GGT; the enzyme accepts glutathione (unsubstituted L-Cys) as a primary natural 
substrate, but at the same time has to accommodates structurally diverse glutathione 
S-conjugates (S-substituted L-Cys) for catabolism of xenobiotics. These apparently contradictory 
demands can be met nicely by strict recognition around the α, β and γ-position (S atom) of the 
Cys residue, while any groups beyond the γ-position remain unbound, probably by sticking out 
of the active site. The stereochemical preference of GGT for the chiral phosphorus (tentatively 
assigned as SP*) shown in this study gives insights into the stereochemical course of the 
catalyzed reaction with glutathione. In this context, the peptidyl phosphorus diesters such as 
2a-A is an ideal ligand for X-ray structural analysis of GGT to define the putative Cys-Gly 
binding site. This line of work is in progress, and the results will be published in due course. 
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Finally, the irreversible nature of the present phosphonate inhibitors is highly advantageous 
over reversible inhibitors for needs to eliminate the GGT activities completely until new 
enzymes are de novo synthesized. This is exactly the major reason why acivicin, a rather weak 
and nonselective inhibitor of mammalian GGT, has been and is still being used widely, 
irrespective of its potent cyto- and neurotoxicity. Therefore the properties of the Cys-Gly binding 
site as probed by the present peptidyl phosphorus esters should give a basis for future molecular 
design for potent and irreversible inhibitors specific for human GGT, as well as for bacterial 
enzymes. 
 
4. Experimental Procedures 
4.1. General methods 
All chemicals were obtained commercially and used without further purification unless 
otherwise sated.  7-(γ-L-Glutamylamino)-4-methylcoumarin (γ-Glu-AMC) was purchased from 
Sigma. Racemic benzyl 2-(N-benzyloxycarbonylamino)-4-phosphonobutanoate (12) was 
synthesized as previously described.
39
 Dry CH2Cl2 and dry triethylamine (Et3N) were prepared 
by distillation from CaH2 and stored over Molecular Sieves 4Å. E. coli γ-glutamyl transpeptidase 
was purified from the periplasmic fraction of a recombinant strain of E. coli K-12 (SH642).
63
 
Human γ-glutamyl transpeptidase HC-GTP (T-72) was a generous gift from Asahi Kasei 
Corporation (Osaka, Japan). The enzyme preparation contained a significant amount of bovine 
serum albumin (BSA) as a stabilizer (GGT content < 1%), but the enzyme was catalytically 
homogeneous and was used without further purification. 









and JOEL JNM-AL400 (400 MHz for 
1
H) spectrophotometers.  
1H chemical shifts (δH) are 
reported downfield of tetramethylsilane as an internal reference (δH 0.0), except for 
measurements in D2O for which sodium 3-(trimethylsilyl)propanesulfonate was used as an 
internal standard (δH 0.0).  Splitting patterns are abbreviated as follows: s, singlet; d, doublet; t, 
triplet, q; quartet; m, multiplet. 
31P chemical shifts (δP) are reported downfield of 85% H3PO4 as 
an external standard (δP 0.0). Infrared spectra were recorded on a HORIBA FT-720 Fourier 
Transform infrared spectrophotometer. Mass spectra were obtained with a JEOL JMS-700 
spectrometer. Mass spectra of the enzyme were recorded on a Sciex API-3000 mass spectrometer 
(PE Sciex) interfaced with an ion-spray ion source. Elemental analyses were performed on a 
Yanaco MT-5. Reactions were monitored by analytical thin layer chromatography (TLC) on 
silica gel 60 F254 plates (Merck, #5715, 0.25 mm). Compounds were purified by flash column 
chromatography on silica gel 60 N (Kanto Kagaku, spherical and neutral, 40-50 mm, No. 
37563-79) or by medium-pressure reversed-phase column chromatography using a Yamazen 
YFLC System with ODS-SM-50B column (Yamazen Co., Osaka, Japan). The spectral data (
1
H 
NMR and/or IR) for known compounds 7a, c, e-g, 9b, 11, 13 and 18 are described in 
Supplementary data. The spectral data supported the structure or are in good agreement with 
those reported (references cited in Supplemental data). 
 
4.2. Synthesis 
4.2.1. (S)-2-Hydroxybutanoic acid (7a). 
(S)-2-Aminobutanoic acid (6a) (4.00 g, 38.8 mmol) was dissolved in 0.5 M H2SO4 (155 mL, 
77.6 mmol). This solution was cooled to 0 C and a solution of NaNO2 (16.0 g, 233 mmol) in 
H2O (40 mL) was added slowly with stirring. After stirring at this temperature for 3 h, the 
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reaction was allowed to warm to room temperature and was stirred for further 2 h. The reaction 
mixture was extracted 7 times with ethyl acetate (7  150 mL). The combined organic extracts 
were washed with sat. NaCl and dried over anhydrous Na2SO4. The solvent was removed in 
vacuo to afford the hydroxy acid 7a (3.98 g) as an oil. This product was used for the preparation 
of compound 9a without purification.   
 
4.2.2. (R)-3-Chloro-2-hydroxypropanoic acid (7c). 
A solution of (R)-(+)-3-chloropropane-1,2-diol (10) (5.0 g, 45.5 mmol) in water (5 mL) was 
placed in a 100 mL test tube. To the bottom of this test tube, 60% (13N) nitric acid (6.99 mL, 
90.9 mmol) was injected slowly by a pipette, keeping the layers separated. The mixture was 
allowed to stand at room temperature without mixing for 3 days until the two layers became a 
clear homogeneous solution. Nitrogen oxide gas (Caution! toxic) was removed from the reaction 
mixture by argon stream in a fuming hood, and the solvent was removed in vacuo to afford crude 
(R)-3-chloro-2-hydroxypropanoic acid (7c) (6.83 g) as a colorless oil. The product was used for 
the preparation of compound 9c without purification. 
 
4.2.3. (S)-2-Hydroxy-3-phenylpropanoic acid (7e). 
Compound 7e was prepared from L-phenylalanine (10.0 g, 60.5 mmol) by the same 
procedure as described for the synthesis of 7a and was purified by recrystallization from a 









 = –21.3 (c 2.35, H2O)]. Anal. calcd 
for C9H10O3: C, 65.05; H, 6.07. Found: C, 64.98; H, 6.04. 
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4.2.4. (S)-2-Hydroxyhexanoic acid (7f). 
Compound 7f was prepared from L-norleucine (8.00 g, 61.0 mmol) by the same procedure 
as described for the synthesis of 7a and was purified by recrystallization from a mixture of 
diethyl ether and hexane (1:12) to give pure 7f as a highly hygroscopic colorless crystalline mass 
(3.18 g, 39%). []D
30
 16.2 (c 1.02, 1 M NaOH) [lit.49 []D
20
 = –16.3 (c 3.92, 1 M NaOH)]. Anal. 
calcd for C6H12O3: C, 54.53; H, 9.15. Found: C, 54.33; H, 9.12. 
 
4.2.5. (R)-2-Hydroxyhexanoic acid (7g). 
Compound 7g was prepared from D-norleucine (8.00 g, 61.0 mmol) by the same procedure 
as described for the synthesis of 7a and was purified by recrystallization from a mixture of 
diethyl ether and hexane (1:12) to yield pure 7g as highly hygroscopic colorless crystalline mass 
(4.19 g, 52%). []D
30
 16. 8 (c 0.99, 1 M NaOH) [lit.49 []D
20
 = –16.3 (c 3.92, 1 M NaOH) for 
the S enantiomer]. Anal. calcd for C6H12O3: C, 54.53; H, 9.15. Found: C, 54.11; H, 9.11. HRMS 
(FAB, glycerol): Calcd for C6H13O3 (MH
+
) 133.0865; found 133.0865. 
 
4.2.6. (S)-Benzyl 2-(2-hydroxybutanamido)acetate (9a). 
Glycine benzyl ester monotosylate (8) (19.3 g, 57.3 mmol), 1-hydroxybenzotriazole 
monohydrate (HOBtH2O) (7.75 g, 57.3 mmol) and N-methylmorpholine (NMM) (6.59 g, 65.1 
mmol) were dissolved in CH2Cl2 (150 mL). This solution was cooled to 0 C. To this solution 
were added the hydroxy acid 7a (3.98 g, 38.3 mmol) and 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) (11.0 g, 57.3 mmol), 
successively. After stirring at room temperature for 18 h, the reaction mixture was concentrated 
in vacuo to remove CH2Cl2. Ethyl acetate (250 mL) was added to the residue, and the resultant 
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mixture was washed successively with 1 N HCl, sat. NaHCO3 and sat. NaCl , and was dried over 
anhydrous Na2SO4. After removal of solvent in vacuo, the residue was purified by flash column 
chromatography (40-60% ethyl acetate in hexane) to afford 9a as a pale yellow oil (4.93 g, 51%).  
[]D
27
 26.2 (c 0.80, EtOH). 1H-NMR (300 MHz, CDCl3): δH 7.39-7.30 (m, 5H, Ph), 7.08 (br, 
1H, NH), 5.18 (s, 2H, PhCH2O), 4.18-4.02 [m, 3H, CH(OH)CONH and Gly-H], 3.08 (br, 1H, 
OH), 1.88 (dqd, J = 14.4, 7.5 and 4.2 Hz, 1H, CH3CHaHb),1.69 (dqd, J = 14.4, 7.5 and 7.2 Hz, 
1H, CH3CHaHb), 0.98 (t, J = 7.5 Hz, 3H, CH3). IR (NaCl) 3396 (br), 1747, 1655, 1533, 1194, 
1128, 1057, 1032, 984, 741, 698 cm
−1
. Anal. calcd for C13H17NO40.2H2O: C, 61.26; H, 6.88; N, 
5.50. Found: C, 61.43; H, 7.07; N, 5.57.  HRMS (FAB, glycerol): Calcd for C13H18NO4 (MH
+
) 
252.1236; found 252.1238. 
 
4.2.7. Benzyl 2-(2-hydroxyacetamido)acetate (9b). 
Compound 9b was prepared from glycolic acid (7b) (2.28 g, 30.0 mmol) and glycine 
derivative 8 (4.87 g, 14.5 mmol) by the same procedure as described for the synthesis of 9a, and 
was purified by flash column chromatography (50% acetone in hexane) to give 9b as a pale 
yellow oil (2.36 g, 73%). Anal. calcd for C11H13NO40.2H2O: C, 58.25; H, 5.95; N, 6.17. Found: 





4.2.8. (R)-Benzyl 2-(3-chloro-2-hydroxypropanamido)acetate (9c). 
Compound 9c was prepared from crude (R)-3-chloro-2-hydroxypropanoic acid (7c) (45.2 
mmol) and glycine derivative 8 (18.4 g, 54.6 mmol) by the same procedure as described for the 
synthesis of 9a and was purified by flash column chromatography (50% ethyl acetate in hexane), 
 33 
followed by recrystallization from ethyl acetate and hexane (1:12) to afford 9c as a colorless 




 35.4 (c 1.08, EtOH). 1H-NMR (300 MHz, 
CDCl3): δH 7.39-7.31 (m, 5H, Ph), 7.24 (br, 1H, NH), 5.20 (s, 2H, PhCH2O), 4.41 [dd, J = 6.0 
and 3.6 Hz, 1H, CH(OH)CONH], 4.16 (dd, J = 18.3 and 5.7 Hz, 1H, Gly-Ha),4.09 (dd, J = 
18.3 and 5.7 Hz, 1H, Gly-Hb),3.91 (dd, J = 11.4 and 3.6 Hz, 1H, ClCHaHb), 3.84 (dd, J = 11.4 
and 6.0 Hz, 1H, ClCHaHb). IR (KBr) 3384 (br), 1736, 1655, 1541, 1221, 1088, 953, 762, 704 
cm
−1
. Anal. calcd for C12H14ClNO4: C, 53.05; H, 5.19; N, 5.16. Found: C, 52.78; H, 5.12; N, 
5.33. 
 
4.2.9. (R)-Benzyl 2-(2-hydroxy-3-iodopropanamido)acetate (9d).   
The chloride 9c (4.00 g, 14.8 mmol) and sodium iodide (22.0 g, 148 mmol) were dissolved 
in acetonitrile (200 mL). The solution was stirred at 80 C for 3 days. Insoluble salt (NaBr) was 
removed by filtration, and the filtrate was evaporated. The residue was dissolved in ethyl acetate 
(300 mL), washed with sat. NaCl (2  200 mL) and was dried over anhydrous Na2SO4. After 
removal of the solvent in vacuo, the residue was purified by flash column chromatography (60% 
ethyl acetate in hexane), followed by recrystallization from a mixture of ethyl acetate and hexane 




 36.2 (c 1.01, 
EtOH). 
1
H-NMR (300 MHz, CDCl3): δH 7.39-7.33 (m, 5H, Ph), 7.21 (br, 1H, NH), 5.20 (s, 2H, 
PhCH2O), 4.21 [ddd, J = 6.3, 5.7 and 3.9 Hz, 1H, CH(OH)CONH], 4.16 (dd, J = 18.3 and 6.0 Hz, 
1H, Gly-Ha),4.11 (dd, J = 18.3 and 4.5 Hz, 1H, Gly-Hb),3.60 (dd, J = 10.2 and 3.9 Hz, 1H, 
ICHaHb), 3.53 (dd, J = 10.2 and 6.3 Hz, 1H, ICHaHb), 3.18 (d, J = 5.7 Hz, 1H, OH). IR (KBr) 
3352 (br), 1741, 1662, 1535, 1392, 1242, 1201, 1078, 957, 715 cm
−1
. Anal. calcd for 
C12H14INO4: C, 39.69; H, 3.89; N, 3.86. Found: C, 39.87; H, 3.97; N 3.84. 
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4.2.10. (S)-Benzyl 2-(2-hydroxy-3-phenylpropanamido)acetate (9e). 
Compound 9e was prepared from 7e (6.13 g, 36.9 mmol) and glycine derivative 8 (14.9 g, 
44.2 mmol) by the same procedure as described for the synthesis of 9a and was purified by 





 66.7 (c 1.00, EtOH). 1H-NMR (300 MHz, CDCl3): δH 7.77 (d, J = 9.3 
Hz) and 7.44-7.22 (m) (10H, 2  Ph), 7.28 (br t, 1H, NH), 5.19 (s, 2H, PhCH2O), 4.37 [dd, J = 
8.7 and 3.6 Hz, 1H, CH(OH)CONH], 4.13 (dd, J = 18.6 and 5.7 Hz) and 4.06 (dd, J = 18.6 and 
5.7 Hz) (2H, Gly-H), 3.27 (dd, J = 13.8 and 3.6 Hz, 1H, PhCHaHb), 2.87 (dd, J = 13.8 and 8.7 
Hz, 1H, PhCHaHb), 2.61 (br, 1H, OH). IR (KBr) 3309 (br), 1759, 1660, 1541, 1456, 1385, 1362, 
1186, 1092, 1036, 964, 746, 704, 588 cm
−1
. Anal. calcd for C18H19NO4: C, 68.99; H, 6.11; N, 
4.47. Found: C, 68.75; H, 6.15; N, 4.35. 
 
4.2.11. (S)-Benzyl 2-(2-hydroxyhexanamido)acetate (9f). 
Compound 9f was prepared from 7f (2.03 g, 15.4 mmol) and glycine derivative 8 (6.22 g, 
18.4 mmol) by the same procedure as described for the synthesis of 9a and was purified by flash 
column chromatography (30 to 50% ethyl acetate in hexane) to give 9f as a colorless oil (4.17 g, 
97%). []D
31
 -30.3 (c 1.03, EtOH). 
1
H-NMR (300 MHz, CDCl3): δH 7.40-7.28 (m, 5H, Ph), 7.17 
(br t, 1H, NH), 5.17 (s, 2H, PhCH2O), 4.14 [m, 1H, CH(OH)CONH], 4.13 (dd, J = 18.0 and 5.7 
Hz, 1H, Gly-Ha), 4.03 (dd, J = 18.0 and 5.7 Hz, 1H, Gly-Hb), 3.43 (d, J = 5.7 Hz, 1H, OH), 
1.89-1.77 [m, 1H, CH3(CH2)2CHaHb], -1.57 [m, 1H, CH3(CH2)2CHaHb], 1.47-1.26 (m, 4H, 
CH3CH2CH2), 0.90 (t, J = 7.1 Hz, 3H, CH3). IR (NaCl) 3398 (br), 2956, 1747, 1657, 1533, 1456, 
1387, 1358, 1194, 1132, 962, 908 cm
−1




280.1549; found 280.1550. Anal. calcd for C15H21NO4: C, 64.50; H, 7.58; N 5.01. Found: C, 
63.94; H, 7.58; N 4.93. 
 
4.2.12. (R)-Benzyl 2-(2-hydroxyhexanamido)acetate (9g). 
Compound 9g was prepared from 7g (2.20 g, 16.7 mmol) and glycine derivative 8 (6.76 g, 
20.0 mmol) by the same procedure as described for the synthesis of 9a and was purified by flash 
column chromatography (30% ethyl acetate in hexane) to give 9g as a clear oil (4.50 g, 97%).  
[]D
27
 30.7 (c 0.94, EtOH). 1H-NMR (300 MHz, CDCl3): δH 7.40-7.28 (m, 5H, Ph), 7.00 (br t, 
1H, NH), 5.19 (s, 2H, PhCH2O), 4.17 [m, 1H, CH(OH)CONH], 4.15 (dd, J = 14.4 and 5.4 Hz, 
1H, Gly-Ha), 4.08 (dd, J = 14.4 and 5.4 Hz, 1H, Gly-Hb), 2.68 (d, J = 5.1 Hz, 1H, OH), 
1.91-1.79 [m, 1H, CH3(CH2)2CHaHb],1.71-1.58 [m, 1H, CH3(CH2)2CHaHb], 1.47-1.26 (m, 4H, 
CH3CH2CH2), 0.91 (t, J = 6.9 Hz, 3H, CH3). IR (NaCl) 3404 (br), 2956, 1749, 1652, 1533, 1456, 
1387, 1358, 1192, 1132, 960, 908 cm
−1
. HRMS (FAB, glycerol): Calcd for C15H22NO4 (MH
+
) 
280.1549; found 280.1548. Anal. calcd for C15H21NO40.2H2O: C, 63.68; H, 7.62; N, 4.95. 
Found: C, 63.77; H, 7.67; N 4.91. 
 
4.2.13. (S)-Methyl 2-hydroxyhexanoate (11). 
Thionyl chloride (2.00 g, 16.8 mmol) was added dropwise to methanol (20 mL) at 0˚C, and 
the mixture was allowed to warm to room temperature. After stirring at room temperature for 30 
min, the hydroxy acid 7f (1.39 g, 10.5 mmol) was added to the solution. After stirring at room 
temperature for 1.5 h, the mixture was concentrated in vacuo. The resulting residue was purified 
by flash column chromatography (40% ethyl acetate in hexane) to afford the methyl ester 11 as a 
colorless oil (1.30 g, 84%). []D
27
 5.50 (c 0.92, EtOH). Anal. calcd for C7H14O3: C, 57.51; H, 
9.65. Found: C, 56.78; H 9.47. 
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4.2.14. (R,S)-Benzyl 2-(N-benzyloxycarbonylamino)-4-(dichlorophosphoryl)butanoate (13). 
Oxalyl chloride (1.41 g, 11.1 mmol) was added to a solution of racemic benzyl 
2-(benzyloxycarbonylamino)-4-phosphonobutanoate (12) (2.01 g, 4.93 mmol) in dry CH2Cl2 (10 
mL) in the presence of a catalytic amount (1 drop) of DMF. Evolution of gas (CO and CO2) was 
observed immediately. The reaction was complete in 2 h at 30˚C. Volatiles were removed by 
vacuum evaporation, followed by removal of trace of HCl by flushing Ar flow to give the 
phosphonic dichloride 13 as an yellow oil. Compound 13 was used fresh for the next reaction 
without purification. 
 
4.2.15. (2R, S)-Benzyl 2-(N-benzyloxycarbonylamino)-4-{(S)-1- 
[N-(benzyloxycarbonylmethyl)carbamoyl]propyl(phenyl)-(RP,SP)-phosphoryl}butanoate 
(14a). 
Phenol (748 mg, 7.94 mmol) in dry CH2Cl2 (5 mL) was added to a solution of the 
phosphonic dichloride 13 (3.52 g, 7.94 mmol) in dry CH2Cl2 (20 mL), and the solution was 
cooled to 65 C. Dry Et3N (804 mg, 7.94 mmol) was added dropwise to the cold solution over 
15 min, and the mixture was stirred at 65 C for 30 min. The mixture was then allowed to warm 
to room temperature. After stirring at room temperature for 2 h, the consumption of 13 (δP 49.2) 
and the formation of monochloro monophenyl ester (δP 39.6) were confirmed with 
31
P NMR. A 
solution of the alcohol 9a (1.33 g, 5.30 mmol) in dry CH2Cl2 (5 mL) was then added to the 
mixture at 0 C, followed by the addition of Et3N (536 mg, 5.30 mmol) to initiate the reaction.  
The mixture was stirred at 0 C for 30 min and was allowed to warm to room temperature.  
After stirring at room temperature for 4 h, the reaction mixture was concentrated in vacuo to 
remove CH2Cl2. To the resulting residue was added ethyl acetate (40 mL), and the insoluble salt 
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was removed by filtration. The crude product contained the desired product 14a (49%, P 28.8, 
28.6, 28.4 and 28.2) along with the corresponding diphenyl phosphonate (13%, P 24.5) and 
dialkyl phosphonate (38%, P 39.5) as byproducts (
31
P NMR). The filtrate was concentrated, and 
the crude product was purified by flash column chromatography (60% ethyl acetate in toluene) 
to afford the phosphonate diester 14a as a mixture of four diastereoisomers (ca. 2:2:1:1) with 
respect to the chiral -carbon and phosphorus (1.99 g, 53%, a pale yellow oil). 1H-NMR (300 
MHz, CDCl3): δH 7.37-7.10 (m, 20H, 4  Ph), 7.20-6.78 (4  br t, 1H, amide NH), 5.79 (br d, J = 
ca. 7 Hz) and 5.59 (d, J = 7.6 Hz) (1H, carbamate NH), 5.23-5.04 (m, 6H, 3  PhCH2O), 
4.85-4.75 [m, 1H, CH(OP)CONH], 4.55-4.37 [m, 1H, NH(CO)CH(CH2)2P], 4.15-3.95 and 
3.80-3.65 (m, 2H, Gly-H), 2.40-1.70 (m, 6H, CH2CH2P and CH3CH2), 0.93 (2  t, J = 7.6 Hz) 
and 0.82 (2  t, J = 7.6 Hz) (3H, CH3). 
31
P-NMR (121 MHz, CDCl3): δP 28.76, 28.57, 28.40, 
28.14. IR (NaCl) 3292 (br), 1743, 1684, 1529, 1313, 1201, 933, 738 cm
−1
. Anal. calcd for 
C38H41N2O10P: C, 63.68; H, 5.77; N, 3.91. Found: C, 63.54; H, 5.78; N 3.74. 
 
4.2.16. (2R,S)-Benzyl 2-(N-benzyloxycarbonylamino)-4-{[N-(benzyloxycarbonylmethyl) 
carbamoyl]methyl(phenyl)-(RP,SP)-phosphono}butanoate (14b). 
Compound 14b was synthesized from the phosphonic dichloride 13 (2.18 g, 4.91 mmol) and 
the alcohol 9b (1.10 g, 4.91 mmol) by the same procedure as described for the synthesis of 14a 
and was purified by flash column chromatography (45% acetone in hexane) to yield pure 14b as 
a mixture of two diastereoisomers (1.31 g, 39%, a pale yellow oil). 
1
H-NMR (300 MHz, CDCl3): 
δH 7.37-7.13 (m, 20H, 4  Ph), 7.04 (br, 1H, amide NH), 5.66 (br, 1H, carbamate NH), 5.18, 5.15 
and 5.08 (3  s, 2H, PhCH2O), 4.66-4.46 [m, 1H, NH(CO)CH(CH2)2P] and 4.46 [dd, 
3
JHP = 15.2 
Hz, J = 8.0 Hz, 3H, CH2(OP)CONH], 4.12-3.92 (m, 2H, Gly-H), 2.43-2.2 (m) and 2.15-1.80 
(m) (4H, CH2CH2P). 
31
P-NMR (121 MHz, CDCl3): δP 29.12, 29.04. IR (NaCl) 3298 (br), 1745, 
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1685, 1535, 1255, 1200, 1065, 937, 741, 696 cm
−1
. Anal. calcd for C36H37N2O10P0.5H2O: C, 
61.98; H, 5.49; N, 4.02. Found: C, 62.11; H, 5.44; N 4.02. 
 
4.2.17. (2R,S)-Benzyl 2-(N-benzyloxycarbonylamino)-4-{(R)-1-[N-(benzyloxycarbonyl- 
methyl)carbamoyl]-2-chloroethyl(phenyl)-(RP,SP)-phosphono}butanoate (14c). 
Compound 14C was synthesized from the phosphonic dichloride 13 (3.26 g, 7.37 mmol) and 
the alcohol 9c (1.33 g, 4.91 mmol) by the same procedure as described for the synthesis of 14a 
and was purified by flash column chromatography (25% ethyl acetate in toluene) to afford pure 
14c as a mixture of four diastereoisomers (1.45 g, 40%, a pale yellow oil). 
1
H-NMR (300 MHz, 
CDCl3): δH 7.37-7.16 (m, 20H, 4  Ph), 7.02 and 6.84 (2  br t, 1H, amide NH), 5.81 (br d, J = 
ca. 6 Hz) and 5.56 (d, J = 7.6 Hz) (1H, carbamate NH), 5.21-5.00 [m, 7H, 3  PhCH2O and 
CH(OP)CONH], 4.68-4.34 [m, 1H, NH(CO)CH(CH2)2P], 4.16 (dd, 
3
JHP = 18.3 Hz and J = 6.3 
Hz) and 3.96 (dd, 
3
JHP = 18.3 Hz and J = 4.8 Hz) (2H, Gly-H), 4.10-3.73 and 3.56-3.48 (2  m, 
2H, and ClCH2), 2.50-2.25 and 2.23-1.96 (2  m, 4H, CH2CH2P). 
31
P-NMR (121 MHz, CDCl3): 
δP 29.86, 29.75, 29.51. IR (NaCl) 3292 (br), 1747, 1684, 1533, 1255, 1200, 1061, 939, 741, 696 
cm
−1
. Anal. calcd for C37H38ClN2O10P: C, 60.29; H, 5.20; N, 3.80. Found: C, 60.22; H, 5.33; N, 
3.68. 
 
4.2.18. (2R,S)-Benzyl 2-(N-benzyloxycarbonylamino)-4-{(R)-1-[N-(benzyloxycarbonyl- 
methyl)carbamoyl]-2-iodoethyl(phenyl)-(RP,SP)-phosphono}butanoate (14d). 
Compound 14d was prepared from the phosphonic dichloride 13 (2.38 g, 5.37 mmol) and the 
alcohol 9d (1.30 g, 3.58 mmol) by the same procedure as described for the synthesis of 14a and 
was purified by flash column chromatography (25% ethyl acetate in toluene) to afford pure 14d 
as a mixture of the diastereoisomers (538 mg, 18%, a pale yellow oil). 
1
H-NMR (300 MHz, 
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CDCl3): δH 7.37-6.95 (m, 21H, 4  Ph and amide NH), 5.81 (br, 1H, carbamate NH), 5.22-5.03 
(m, 6H, 3  PhCH2O), 4.97-4.88 [m, 1H, CH(OP)CONH], 4.60-4.44 [m, 1H, 
NH(CO)CH(CH2)2P], 4.14 (dd, 
3
JHP = 18.3 Hz and J = 6.0 Hz) and 3.97 (dd, 
3
JHP = 18.3 Hz and 
J = 4.5 Hz) (2H, Gly-H), 3.64-3.50 and 3.21-3.19 (2  m, 2H, ICH2), 2.47-1.96 (m, 4H, 
CH2CH2P).  
31
P-NMR (121 MHz, CDCl3): δP 29.59, 29.47, 29.32. IR (NaCl) 3288 (br), 1743, 
1682, 1489, 1456, 1255, 1200, 1053, 939, 754, 696 cm
−1
. Anal. calcd for C37H38IN2O10P: C, 
53.63; H, 4.62; N, 3.38. Found: C, 54.04; H, 4.72; N, 3.33. HRMS (FAB, glycerol): Calcd for 
C37H39IN2O10P (MH
+
) 829.1387; found 829.1375. 
 
4.2.19. (2R,S)-Benzyl 2-(N-benzyloxycarbonylamino)-4-{(S)-1-[N-(benzyloxycarbonyl- 
methyl) carbamoyl]-2-phenylethyl(phenyl)-(RP,SP)-phosphono}butanoate (14e). 
Compound 14e was prepared from the phosphonic dichloride 13 (2.18 g, 4.91 mmol) and the 
alcohol 9e (1.54 g, 4.91 mmol) by the same procedure as described for the synthesis of 14a and 
was purified by flash column chromatography (30% ethyl acetate in toluene) to afford pure 14e 
as a mixture of four diastereoisomers (804 mg, 21%, a pale yellow oil). 
1
H-NMR (300 MHz, 
CDCl3): δH 7.39-6.97 (m, 25H, 5  Ph), 6.57 (br t, 1H, amide NH), 5.57 (br d, 1H, carbamate 
NH), 5.28-5.04 [m, 7H, 3  PhCH2O and CH(OP)CONH], 4.41 and 4.28 [2  m, 1H, 
NH(CO)CH(CH2)2P], 4.02-3.83 (m) and 3.62 (dd, J = 18.3 and 4.8 Hz) (2H, Gly-H), 3.33 (d, J 
= 12.6 Hz) and 3.25-2.89 (m) (2H, PhCH2), 2.29-1.76 (m), 1.75-1.50 (m), 1.49-1.27 (m) (4H, 
CH2CH2P). 
31
P-NMR (121 MHz, CDCl3): δP 29.98, 29.85, 28.99, 28.78. IR (NaCl) 3294 (br), 
1745, 1687, 1529, 1456, 1387, 1346, 1254, 1200, 935, 752, 698, 580 cm
−1
. Anal. calcd for 
C43H43N2O10P: C, 66.32; H, 5.57; N, 3.60. Found: C, 66.21; H, 5.55; N 3.62. 
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4.2.20. (2R,S)-Benzyl 2-(N-benzyloxycarbonylamino)-4-{(S)-1-[N-(benzyloxycarbonyl- 
methyl)carbamoyl]pentyl(phenyl)-(RP,SP)-phosphono}butanoate (14f). 
Compound 14f was prepared from the phosphonic dichloride 13 (3.26 g, 7.37 mmol) and the 
alcohol 9f (1.37 g, 4.91 mmol) by the same procedure as described for the synthesis of 14a and 
was purified by flash column chromatography (35% ethyl acetate in toluene) to afford pure 14f 
as a mixture of four diastereoisomers (1.96 g, 54%, a pale yellow oil). 
1
H-NMR (300 MHz, 
CDCl3): δH 7.36-7.15 (m, 20H, 4  Ph), 7.05-6.76 (4  br t, 1H, amide NH), 5.83 (br d, J = 5.1 
Hz) and 5.60 (d, J = 7.8 Hz) (1H, carbamate NH), 5.23-5.04 (m, 6H, 3  PhCH2O), 4.97-4.87 [m, 
1H, CH(OP)CONH], 4.57-4.43 [m, 1H, NH(CO)CH(CH2)2P], 4.10 (dd, 
3
JHP = 18.3 Hz and J = 
6.0 Hz), 3.96 (dd, 
3
JHP = 18.3 Hz and J = 4.8 Hz) and 4.15-3.77 (m) (2H, Gly-H), 2.42-2.25 
(m), 2.25-1.94 (m) and 1.93-1.63 (m) [6H, CH2CH2P and CH3(CH2)2CH2], 1.31 and 1.17 (2  m, 
4H, CH3CH2CH2), 0.86 (m) and 0.78 (t, J = 7.1 Hz) (3H, CH3). 
31
P-NMR (121 MHz, CDCl3): δP 
28.80, 28.59, 28.37, 28.11. IR (NaCl) 3290 (br), 2956, 1747, 1684, 1591, 1533, 1489, 1456, 
1248, 1201, 1047, 1005, 935 cm
−1
. Anal. calcd for C40H45N2O10P: C, 64.51; H, 6.09; N, 3.76. 
Found: C, 64.57; H, 6.08; N 3.70. 
 
4.2.21. (2R,S)-Benzyl 2-(N-benzyloxycarbonylamino)-4-{(R)-1-[N-(benzyloxycarbonyl- 
methyl)carbamoyl]pentyl(phenyl)-(RP,SP)-phosphono}butanoate (14g). 
Compound 14g was prepared from the phosphonic dichloride 13 (3.67 g, 8.28 mmol) and the 
alcohol 9g (2.08 g, 7.45 mmol) by the same procedure as described for the synthesis of 14a and 
was purified by flash column chromatography (40% ethyl acetate in toluene) to afford pure 14g 
as a mixture of four diastereoisomers (1.57 g, 28%, a pale yellow oil). 
1
H-NMR (300 MHz, 
CDCl3): δH 7.37-7.12 (m, 20H, 4  Ph), 7.05-6.76 (4  br t, 1H, amide NH), 5.81 (br d, J = ca. 7 
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Hz) and 5.58 (d, J = 7.5 Hz) (1H, carbamate NH), 5.21-5.04 (m, 6H, 3  PhCH2O), 4.98-4.85 [m, 
1H, CH(OP)CONH], 4.59-4.44 [m, 1H, NH(CO)CH(CH2)2P], 4.10 (dd, 
3
JHP = 18.0 Hz and J = 
6.0 Hz), 3.97 (dd, 
3
JHP = 18.0 Hz and J = 5.4 Hz) and 4.15-3.93 (m) (2H, Gly-H), 2.42-2.23 
(m), 2.20-1.94 (m) and 1.93-1.63 (m) [6H, CH2CH2P and CH3(CH2)2CH2], 1.31 and 1.17 (2  m, 
4H, CH3CH2CH2), 0.86 and 0.78 (2  m, 3H, CH3). 
31
P-NMR (121 MHz, CDCl3): δP 28.80, 
28.59, 28.37, 28.11. IR (NaCl) 3290 (br), 2956, 1745, 1682, 1589, 1529, 1491, 1454, 1254, 1201, 
1047, 1005, 935 cm
−1
. Anal. calcd for C40H45N2O10P0.5H2O: C, 63.74; H, 6.15; N, 3.72. Found: 





4.2.22. (2R,S)-Benzyl 2-(N-benzyloxycarbonylamino)-4-{(S)-1-methoxycarbonylpentyl- 
(phenyl)-(RP,SP)-phosphono}butanoate (15). 
Compound 15 was prepared from the phosphonic dichloride 13 (2.24 g, 5.07 mmol) and the 
alcohol 11 (494 mg, 3.38 mmol) by the same procedure as described for the synthesis of 14a and 
was purified by flash column chromatography (40% ethyl acetate in hexane) to afford pure 15 as 
a mixture of four diastereoisomers (763 mg, 37%, a pale yellow oil). 
1
H-NMR (300 MHz, 
CDCl3): δH 7.38-7.12 (m, 15H, 3  Ph), 5.61 (br) and 5.50 (br d, J = ca. 7 Hz) (1H, carbamate 
NH), 5.23-5.07 (m, 6H, 3  PhCH2O), 4.96-4.82 [m, 1H, CH(OP)CO2Me], 4.57-4.38 [m, 1H, 
NH(CO)CH(CH2)2P], 3.68 and 3.60 (2  s, 3H, CH3O), 2.44-2.25 (m) and 2.25-1.90 (m) (4H, 
CH2CH2P), 1.90-1.75 (m) and 1.74-1.60 (m) [2H, CH3(CH2)2CH2], 1.32 and 1.14 (2  m, 4H, 
CH3CH2CH2), 0.88 (t, J = 6.3 Hz) and 0.77 (t, J = 6.6 Hz) (3H, CH3). 
31
P-NMR (121 MHz, 
CDCl3): δP 29.61, 29.51, 28.05, 27.94. IR (NaCl) 3265 (br), 2956, 1753, 1724, 1591, 1493, 1454, 
1344, 1255, 1205, 1053, 1026, 931, 756, 696 cm
−1
. Anal. calcd for C32H38NO9P: C, 62.84; H, 
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6.26; N, 2.29. Found: C, 62.71; H, 6.26; N, 2.26. 
 
4.2.23. (2R,S)-Benzyl 2-(N-benzyloxycarbonylamino)-4-{(S)-1-[N-(benzyloxycarbonyl- 
methyl)carbamoyl]propyl(methyl)-(RP,SP)-phosphono}butanoate (16). 
Compound 16 was prepared from the phosphonic dichloride 13 (3.18 g, 7.17 mmol), dry 
methanol (230 mg, 7.17 mmol) and the alcohol 9a (1.20 g, 4.78 mmol) by the same procedure as 
described for the synthesis of 14a and was purified by flash column chromatography (40% ethyl 
acetate in diethyl ether) to afford pure 16 as a mixture of four diastereoisomers (624 mg, 20%, a 
pale yellow oil). 
1
H-NMR (300 MHz, CDCl3): δH 7.40-7.19 (m, 15H, 3  Ph), 7.11 (br, 1H, 
amide NH), 5.79 (br t, J = ca. 8 Hz, 1H, carbamate NH), 5.20-5.06 (m, 6H, 3  PhCH2O), 
4.87-4.75 [m, 1H, CH(OP)CONH], 4.55-4.35 [m, 1H, NH(CO)CH(CH2)2P], 4.15-3.94 and 
3.82-3.63 (2  m, 2H, Gly-H), 3.71 and 3.59 (2  d, 3JHP = 11.1 Hz, 3H, CH3O), 2.33-2.10 (m) 
and 2.10-1.71 (m) (6H, CH2CH2P and CH3CH2), 0.95 (t, J = 7.5 Hz, 3H, CH3). 
31
P-NMR (121 
MHz, CDCl3): δP 33.24, 33.05, 32.79. IR (NaCl) 3275 (br), 2952, 1743, 1724, 1682, 1531, 1456, 
1244, 1215, 1196, 1043, 995, 739, 698 cm
−1
. HRMS (FAB, glycerol): Calcd for C33H40O10N2P 
(MH
+




butanoic acid (2a-A). 
(2R,S)-2-Amino-4-{(S)-1-[N-(carboxymethyl)carbamoyl]propyl(phenyl)-(RP*)-phosphono}-
butanoic acid (2a-B). 
The phosphonate diester 14a (227 mg, 0.317 mmol, a mixture of four diastereoisomers) was 
dissolved in a mixture of methanol (20 mL) and H2O (4 mL) containing acetic acid (95.0 mg, 
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1.58 mmol). Hydrogen gas was passed through the solution in the presence of 5% Pd/C for 2 h at 
room temperature. The consumption of 14a was monitored by TLC (ethyl acetate/hexane, 2:1, 
phosphomolybdate, Rf = 0.5), and the formation of product was confirmed by TLC 
(butan-1-ol/acetic acid/H2O, 5:2:2, ninhydrin, Rf = 0.55). Pd/C was removed by filtration through 
Celite, and the filtrate was evaporated. The residue was purified by medium-pressure 
reversed-phase column chromatography on ODS-S-50B (Yamazen Co., Osaka, Japan). The 
column was eluted (6 mL/min) with a linear gradient of 40 to 60% methanol in H2O. The 
UV-positive (254 nm) fractions containing the product (TLC, butan-1-ol/acetic acid/H2O, 5:2:2, 
ninhydrin) were collected and lyophilized to afford the SP* isomer (2a-A) (41.3 mg, 33%, 
slow-eluted isomer, eluted at 50% methanol) and the RP* isomer (2a-B) (17.0 mg, 13%, 
fast-eluted isomer, eluted at 40% methanol) each as a colorless solid. 
Compound 2a-A (a mixture of two diastereoisomers). 
1
H-NMR (300 MHz, D2O): δH 7.47 (t, 
J = 8.0 and 7.8 Hz, 2H),7.33 (t, J = 7.8 Hz, 1H) and 7.26 (d, J = 7.8 Hz, 2H) (Ph), 4.98-4.86 [m, 
1H, CH(OP)CONH], 4.00 (d, J = 18.0 Hz, 1H, Gly-Ha), 3.93 (d, J = 18.0 Hz, 1H, Gly-Hb), 
3.92-3.85 [m, 1H, NH2(CO2H)CH(CH2)2P], 2.48-2.19 (m, 4H, CH2CH2P), 1.90-1.76 (m, 2H, 
CH3CH2), 0.85 (t, J = 7.5 Hz, 3H, CH3). 
31
P-NMR (121 MHz, D2O): δP 30.91. IR (KBr) 3435 
(br), 2976, 1668, 1489, 1205, 1051, 1007, 943, 769, 690 cm
−1
. Anal. calcd for 
C16H23N2O8P1.25H2O: C, 45.23; H, 6.05; N, 6.59. Found: C, 45.28; H, 5.90; N, 6.74. HRMS 
(FAB, glycerol): Calcd for C16H24N2O8P (MH
+
) 403.1270; found 403.1263.   
Compound 2a-B (a mixture of two diastereoisomers). 
1
H-NMR (400 MHz, D2O):δH 7.44 (t, 
J = 8.1 Hz), 7.32 (t, J = 8.1 Hz), 7.21 (d, J = 8.4 Hz), 6.98 (t, J = 7.6 Hz) and 6.91 (d, J = 8.0 Hz, 
1H) (5H, Ph), 4.92-4.85 (m) and 4.61 (ddd, 
3
JHP= 9.4 Hz, J = 4.9 and 4.9 Hz) [1H, 
CH(OP)CONH], 3.99 (s, 1H, Gly-Ha), 3.78 (s, 1H, Gly-Hb), 3.88 (t, J = 5.4 Hz) and 3.82 (dd, 
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J = 11.6 and 5.4 Hz) [1H, NH2(CO2H)CH(CH2)2P], 2.47-2.31 (m), 2.35-2.20 (m) and 2.20-2.05 
(m) (4H, CH2CH2P), 1.95-1.76 (m, 2H, CH3CH2), 0.96 and 0.93 (2 × t, J = 7.4 Hz, 3H, CH3). 
31
P-NMR (121 MHz, D2O): δP 30.71. IR (KBr) 3429 (br), 2978, 1668, 1489, 1202, 1051, 1009, 
941, 769, 690 cm
−1
. HRMS (FAB, glycerol): Calcd for C16H24N2O8P (MH
+




phosphono}butanoic acid (2b).   
Compound 2b was prepared from 14b (500 mg, 0.727 mmol, a mixture of two 
diastereoisomers) by the same procedure as described for the synthesis of 2a and was purified by 
medium-pressure reversed-phase column chromatography (ODS-S-50B) with a linear gradient of 
5 to 35% methanol in H2O. The UV-positive (254 nm) fractions containing the product (TLC, 
butan-1-ol/acetic acid/H2O, 5:2:2, ninhydrin) eluted at 30% methanol were collected and 
lyophilized to give compound 2b as a colorless solid (79.2 mg, 29%) (a mixture of four 
stereoisomers). 
1
H-NMR (300 MHz, D2O):δH 7.47 (dd, J = 7.8 and 7.4 Hz, 2H),7.33 (t, J = 7.4 
Hz, 1H) and 7.26 (d, J = 7.8 Hz, 2H) (Ph), 4.80-4.68 [m, 2H, CH2(OP)CONH], 3.97 (s, 2H, 
Gly-H), 3.91 [br t, 1H, NH2(CO2H)CH(CH2)2P], 2.48-2.22 (m, 4H, CH2CH2P). 
31
P-NMR (121 
MHz, D2O): δP 31.73, 31.70. IR (KBr) 3419 (br), 2943, 1670, 1489, 1228, 1201, 1070, 1024, 941, 
769, 690 cm
−1
. Anal. calcd for C14H19N2O8P1.5H2O: C, 41.90; H, 5.53; N, 6.98. Found: C, 
41.97; H, 5.50; N 7.10. HRMS (FAB, glycerol): Calcd for C14H20N2O8P (MH
+
) 375.0957; found 





phosphono}butanoic acid (2c-A). 
(2R,S)-2-Amino-4-{(R)-1-[N-(carboxymethyl)carbamoyl]-2-chloroethyl(phenyl)-(RP*)- 
phosphono}butanoic acid (2c-B). 
Compound 2c was prepared from 14c (379 mg, 0.515 mmol) by the same procedure as 
described for the synthesis of 2a and was purified by medium-pressure reversed-phase column 
chromatography (ODS-S-50B) with a linear gradient of 30 to 50% methanol in H2O. The 
UV-positive (254 nm) fractions containing the product (TLC, butan-1-ol/acetic acid/H2O, 5:2:2, 
ninhydrin) were collected and lyophilized to afford the SP* isomer (2c-A) (72.9 mg, 34%, 
slow-eluted isomer, eluted at 50% methanol) and the RP* isomer (2c-B) (28.9 mg, 13%, 
fast-eluted isomer, eluted at 35% methanol) each as a colorless solid. 
Compound 2c-A (a mixture of two diastereoisomers). 
1
H-NMR (400 MHz, D2O):δH 7.47 (t, 
J = 8.0 Hz), 7.34 (t, J = 8.0 Hz), 7.29 (d, J = 8.0 Hz), 6.98 (t, J = 7.6 Hz) and 6.91 (d, J = 8.4 
Hz) (5H, Ph), 5.29 and 4.96 [2  m, 1H, CH(OP)CONH], 4.10-3.89 (m, 4H, ClCH2 and Gly-H), 
3.84-3.78 [m, 1H, NH2(CO2H)CH(CH2)2P], 2.53-2.11 (m, 4H, CH2CH2P). 
31
P-NMR (121 MHz, 
D2O): δP 31.42. IR (KBr) 3427 (br), 2944, 1674, 1491, 1228, 1203, 1070, 947, 768, 690 cm
−1
.  
Anal. calcd for C15H20ClN2O8P0.43H2O: C, 41.85; H, 4.88; N, 6.51. Found: C, 42.12; H, 4.97; 









) 425.0695; found 425.0698.   
Compound 2c-B (a mixture of two diastereoisomers). 
1
H-NMR (400 MHz, D2O):δH 7.45 (t, 
J = 8.4 Hz),7.32 (t, J = 8.4 Hz), 7.24 (d, J = 8.4 Hz), 6.98 (t, J = 7.6 Hz) and 6.91 (d, J = 8.4 Hz) 
(5H, Ph), 5.24-5.18 (m) and 4.96 (m) [1H, CH(OP)CONH], 4.04-3.79 [m, 5H, ClCH2, Gly-H 
and NH2(CO2H)CH(CH2)2P], 2.54-2.09 (m, 4H, CH2CH2P).
 31
P-NMR (121 MHz, D2O): δP 
31.31; IR (KBr) 3427 (br), 2945, 1674, 1491, 1228, 1203, 1070, 947, 768, 690 cm
−1
. Anal. calcd 
for C15H20ClN2O8PH2O: C, 40.87; H, 5.03; N, 6.36. Found: C, 40.73; H, 4.89; N, 6.35.  HRMS 
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phosphono}butanoic acid (2d-A). 
To a solution of the phosphonate diester 14d (257 mg, 0.310 mmol) in dry nitromethane (4 
mL) was added anisole (403 mg, 3.72 mmol) and aluminum chloride (248 mg, 1.86 mmol) at 
room temperature. After stirring at room temperature for 1 h, the reaction mixture was diluted 
with 1 N HCl (20 mL) and washed with diethyl ether (3  30 mL) to remove anisole and 
nitromethane. The aqueous layer was concentrated in vacuo to ca. 10 mL (do not dry up) and 
was directly applied to the medium-pressure reversed-phase column chromatography on 
ODS-S-50B. The column was eluted (6 mL/min) with a linear gradient of 30 to 50% methanol in 
H2O. The UV-positive (254 nm) fractions containing the product (TLC, butan-1-ol/acetic 
acid/H2O, 5:2:2, ninhydrin) were collected and lyophilized to afford the SP* isomer (2d-A) (35.0 
mg, 22%, slow-eluted isomer, eluted at 50% methanol) as colorless solid and the RP* isomer 
(2s-B) (trace, detected by TLC, fast-eluted isomer, eluted at 40% methanol).   
Compound 2c-A (a mixture of two diastereoisomers). 
1
H-NMR (400 MHz, D2O):δH 7.48 (t, 
J = 7.8 Hz),7.34 (t, J = 7.8 Hz), 7.31 (d, J = 7.8 Hz), 6.98 (t, J = 7.6 Hz) and 6.91 (d, J = 7.6 Hz, 
1H) (5H, Ph), 5.07 (ddd, 
3
JHP= 8.0 Hz, J = 4.0 and 4.0 Hz) and 4.73-4.67 (m) [1H, 
CH(OP)CONH], 4.12-3.91 [m, 3H, NH(CO)CH(CH2)2P and Gly-H], 3.66-3.38 (m, 2H, ICH2), 
2.52-2.11 (m, 4H, CH2CH2P). 
31
P-NMR (121 MHz, D2O): δP 31.19. IR (KBr) 3435 (br), 2945, 
1668, 1633, 1489, 1228, 1201, 1053, 497, 768, 690 cm
−1
. Anal. calcd for C15H20IN2O8PH2O: C, 








phosphono}butanoic acid (2e-A). 
(2R,S)-2-Amino-4-{(S)-1-[N-(carboxymethyl)carbamoyl]-2-phenylethyl(phenyl)-(RP*)- 
phosphono}butanoic acid (2e-B). 
Compound 2e was prepared from 14e (253 mg, 0.325 mmol)) by the same procedure as 
described for the synthesis of 2a and was purified by medium-pressure reversed-phase column 
chromatography (ODS-S-50B) with a linear gradient of 40 to 60% methanol in H2O. The 
UV-positive (254 nm) fractions containing the product (TLC, butan-1-ol/acetic acid/H2O, 5:2:2, 
ninhydrin) were collected and lyophilized to afford the SP* isomer (2c-A) (59.3 mg, 39%, 
slow-eluted isomer, eluted at 60% methanol) and the RP* isomer (2c-B) (33.8 mg, 22%, 
fast-eluted isomer, eluted at 55% methanol) each as a colorless solid. 
Compound 2e-A (a mixture of two diastereoisomers). 
1
H-NMR (300 MHz, D2O): δH 7.40 (t, 
J = 7.8 Hz, 2H), 7.36-7.25 (m, 4H), 7.23-7.17 (m, 2H) and 7.03 (d, J = 8.1 Hz, 2H) (2 × Ph), 
5.12 [m, 1H, CH(OP)CONH], 3.88 (d, J = 17.4 Hz) and 3.80 (d, J = 17.4 Hz) (2H, Gly-H), 
3.80-3.75 [m, 1H, NH2(CO2H)CH(CH2)2P], 3.18 (dd, J = 13.8 and 4.2 Hz) and 3.10 (dd, J = 13.8 
and 8.1 Hz) (2H, PhCH2), 2.28-2.07 (m, 4H, CH2CH2P). 
31
P-NMR (121 MHz, D2O): δP 30.79. 
IR (KBr) 3446 (br), 3064, 1668, 1491, 1252, 1211, 1053, 1007, 947, 758, 690 cm
−1
. Anal. calcd 
for C21H25N2O8P0.5H2O: C, 53.28; H, 5.54; N, 5.92. Found: C, 53.45; H, 5.44; N, 5.99. HRMS 
(FAB, glycerol): Calcd for C21H26N2O8P (MH
+
) 465.1427; found 465.1428.   
Compound 2e-B (a mixture of two diastereoisomers). 
1
H-NMR (300 MHz, D2O):δH  
7.45-7.24 (m, 8H) and 7.14 (d, J = 8.4 Hz, 2H) (2 × Ph), 5.12 [m, 1H, CH(OP)CONH], 3.71 (s, 
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2H, Gly-H), 3.74-3.64 [m, 1H, NH2(CO2H)CH(CH2)2P], 3.25 (dd, J = 14.4 and 3.6 Hz) and 
3.11 (dd, J = 14.4 and 8.4 Hz) (2H, PhCH2), 2.18-1.81 (m, 4H, CH2CH2P). 
31
P-NMR (121 MHz, 
D2O): δP 30.64. IR (KBr) 3419 (br), 3064, 1668, 1491, 1456, 1404, 1340, 1250, 1203, 1055, 
1009, 964, 941, 764, 700 cm
−1
. Anal. calcd for C21H25N2O8P1.5H2O: C, 51.32; H, 5.74; N, 5.70. 
Found: C, 51.26; H, 5.86; N, 5.66. HRMS (FAB, glycerol): Calcd for C21H26N2O8P (MH
+
) 




utanoic acid (2f-A). 
(2R,S)-2-Amino-4-{(S)-1-[N-(carboxymethyl)carbamoyl]pentyl(phenyl)-(RP*)-phosphono}- 
butanoic acid (2f-B). 
Compound 2f was prepared from 14f (447 mg, 0.601 mmol) by the same procedure as 
described for the synthesis of 2a and was purified by medium-pressure reversed-phase column 
chromatography (ODS-S-50B) with a linear gradient of 20 to 60% methanol in H2O. The 
UV-positive (254 nm) fractions containing the product (TLC, butan-1-ol/acetic acid/H2O, 5:2:2, 
ninhydrin) were collected and lyophilized to afford the SP* isomer (2f-A) (157 mg, 56%, 
slow-eluted isomer, eluted at 60% methanol) and the RP* isomer (2f-B) (71.0 mg, 25%, 
fast-eluted isomer, eluted at 60% methanol) each as a colorless solid. 
Compound 2f-A (a mixture of two diastereoisomers). 
1
H-NMR (300 MHz, D2O):δH 7.47 (t, 
J = 7.8 Hz, 2H),7.33 (t, J = 7.8 Hz, 1H) and 7.26 (d, J = 7.8 Hz, 2H) (Ph), 4.97-4.87 [m, 1H, 
CH(OP)CONH], 4.02 (d, J = 18.0 Hz, 1H, Gly-Ha), 3.95 (d, J = 18.0 Hz, 1H, Gly-Hb), 
3.93-3.86 [m, 1H, NH2(CO2H)CH(CH2)2P], 2.45-2.18 (m, 4H, CH2CH2P), 1.86-1.65 [m, 2H, 




MHz, D2O): δP 30.90. IR (KBr) 3435 (br), 1664, 1491, 1207, 1041, 1007, 941, 766, 690 cm
−1
. 
Anal. calcd for C18H27N2O8PH2O: C, 48.21; H, 6.52; N, 6.25. Found: C, 48.39; H, 6.30; N, 6.27. 
HRMS (FAB, glycerol): Calcd for C18H28N2O8P (MH
+
) 431.1583; found 431.1571.   
Compound 2f-B (a mixture of two diastereoisomers). 
1
H-NMR (300 MHz, D2O):δH 7.44 
(dd, J = 7.8 and J = 7.4 Hz, 2H),7.31 (t, J = 7.4 Hz, 1H) and 7.21 (d, J = 7.8 Hz, 2H) (Ph), 
4.97-4.87 [m, 1H, CH(OP)CONH], 3.88 [t, J = 5 Hz, 1H, NH2(CO2H)CH(CH2)2P], 3.80 (s, 2H, 
Gly-H), 2.44-2.21 (m, 4H, CH2CH2P), 1.93-1.83 [m, 2H, CH3(CH2)2CH2], 1.42-1.26 (m, 4H, 
CH3CH2CH2), 0.87 (t, J = 6.9 Hz, 3H, CH3). 
31
P-NMR (121 MHz, D2O): δP 30.60 and 30.56. IR 
(KBr) 3431 (br), 2958, 1664, 1491, 1205, 1047, 1018, 937, 764, 690 cm
−1
. Anal. calcd for 
C18H27N2O8P1.5H2O: C, 47.26; H, 6.61; N, 6.12. Found: C, 47.35; H, 6.35; N, 6.17. HRMS 
(FAB, glycerol): Calcd for C18H28N2O8P (MH
+




butanoic acid (2g-A). 
(2R,S)-2-Amino-4-{(R)-1-[N-(carboxymethyl)carbamoyl]pentyl(phenyl)-(SP*)-phosphono}-
butanoic acid (2g-B). 
Compound 2g was prepared from 14g (300 mg, 0.403 mmol) by the same procedure as 
described for the synthesis of 2a and was purified by medium-pressure reversed-phase column 
chromatography (ODS-S-50B) with a linear gradient of 40 to 60% methanol in H2O. The 
UV-positive (254 nm) fractions containing the product (TLC, butan-1-ol/acetic acid/H2O, 5:2:2, 
ninhydrin) were collected and lyophilized to afford the RP* isomer (2g-A) (97.3 mg, 52%, 
slow-eluted isomer, eluted at 60% methanol) and the SP* isomer (2g-B) (46.9 mg, 25%, 
fast-eluted isomer, eluted at 60% methanol) each as a colorless solid. 
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Compound 2g-A (a mixture of two diastereoisomers). 
1
H-NMR (300 MHz, D2O):δH 7.47 
(dd, J = 8.1 and 7.5 Hz, 2H),7.33 (t, J = 7.5 Hz, 1H) and 7.26 (d, J = 8.1 Hz, 2H) (Ph), 4.97-4.87 
[m, 1H, CH(OP)CONH], 4.01 (d, J = 17.7 Hz, 1H, Gly-Ha), 3.94 (d, J = 17.7 Hz, 1H, 
Gly-Hb), 3.93-3.85 [m, 1H, NH2(CO2H)CH(CH2)2P], 2.47-2.18 (m, 4H, CH2CH2P), 1.85-1.66 
[m, 2H, CH3(CH2)2CH2], 1.24-1.11 (m, 4H, CH3CH2CH2), 0.78 (t, J = 6.0 Hz, 3H, CH3). 
31
P-NMR (121 MHz, D2O): δP 30.85. IR (KBr) 3419 (br), 2956, 1668, 1491, 1207, 1039, 1007, 
941, 767, 690 cm
−1
. Anal. calcd for C18H27N2O8P0.5H2O: C, 49.20; H, 6.42; N, 6.38. Found: C, 
49.12; H, 6.33; N, 6.42. HRMS (FAB, glycerol): Calcd for C18H28N2O8P (MH
+
) 431.1583; found 
431.1593.   
Compound 2g-B (a mixture of two diastereoisomers). 
1
H-NMR (300 MHz, D2O):δH 7.44 
(dd, J = 7.8 and 7.4 Hz, 2H),7.31 (t, J = 7.4 Hz, 1H) and 7.21 (d, J = 7.8 Hz, 2H) (Ph), 4.97-4.87 
[m, 1H, CH(OP)CONH], 3.89 [t, J = 5 Hz, 1H, NH2(CO2H)CH(CH2)2P], 3.82 (s, 2H, Gly-H), 
2.44-2.21 (m, 4H, CH2CH2P), 1.93-1.83 [m, 2H, CH3(CH2)2CH2], 1.42-1.25 (m, 4H, 
CH3CH2CH2), 0.87 (t, J = 6.9 Hz, 3H, CH3). 
31
P-NMR (121 MHz, D2O): δP 30.56 and 30.53. IR 
(KBr) 3429 (br), 2958, 1668, 1491, 1203, 1045, 1009, 939, 766, 690 cm
−1
. HRMS (FAB, 
glycerol): Calcd for C18H28N2O8P (MH
+






Compound 3 was prepared from 15 (479 mg, 0.784 mmol) by the same procedure as 
described for the synthesis of 2a and was purified by medium-pressure reversed-phase column 
chromatography (ODS-S-50B) with a linear gradient of 40 to 60% methanol in H2O. The 
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UV-positive (254 nm) fractions containing the product (TLC, butan-1-ol/acetic acid/H2O, 5:2:2, 
ninhydrin) were collected and lyophilized to afford the SP* isomer (3-A) (140 mg, 46%, 
slow-eluted isomer, eluted at 60% methanol) and the RP* isomer (3-B) (67.3 mg, 22%, 
fast-eluted isomer, eluted at 60% methanol) each as a colorless solid. 
Compound 3-A (a mixture of two diastereoisomers). 
1
H-NMR (300 MHz, D2O):δH 7.46 (dd, 
J = 7.5 and 7.5 Hz, 2H),7.32 (t, J = 7.5 Hz, 1H) and 7.24 (d, J = 7.5 Hz, 2H) (Ph), 5.00 [m, 1H, 
CH(OP)CO2Me], 3.85 [m, 1H, NH2(CO2H)CH(CH2)2P], 3.79 (s, 3H, CH3O), 2.45-2.17 (m, 4H, 
CH2CH2P), 1.84-1.68 [m, 2H, CH3(CH2)2CH2], 1.24-1.07 (m, 4H, CH3CH2CH2), 0.78 (t, J = 6.6 
Hz, 3H, CH3). 
31
P-NMR (121 MHz, D2O): δP 31.36. IR (KBr) 3467 (br), 2958, 1747, 1631, 1592, 
1491, 1406 ,1348, 1288, 1207, 1080, 1024, 935, 769, 690, 542 cm
−1
. Anal. calcd for 
C17H26NO7P0.5H2O: C, 51.51; H, 6.87; N, 3.53. Found: C, 51.40; H, 6.88; N. 3.64. HRMS 
(FAB, glycerol): Calcd for C17H27NO7P (MH
+
) 388.1525; found 388.1519.   
Compound 3-B (a mixture of two diastereoisomers). 
1
H-NMR (300 MHz, D2O):δH 7.46 (dd, 
J = 7.8 and 7.8 Hz, 2H),7.32 (t, J = 7.8 Hz, 1H) and 7.23 (d, J = 7.8 Hz, 2H) (Ph), 5.06 [m, 1H, 
CH(OP)CO2Me], 3.83 [m, 1H, NH2(CO2H)CH(CH2)2P], 3.69 and 3.68 (2  s, 3H, CH3O), 
2.45-2.14 (m, 4H, CH2CH2P), 1.96-1.83 [m, 2H, CH3(CH2)2CH2], 1.45-1.24 (m, 4H, 
CH3CH2CH2), 0.87 (t, J = 6.9 Hz, 3H, CH3). 
31
P-NMR (121 MHz, D2O): δP 30.84. IR (KBr) 
3467 (br), 2954, 1749, 1616, 1592, 1492, 1410, 1348 ,1261 ,1211, 1085, 1055, 1028, 933, 766, 
692, 555 cm
−1
. Anal. calcd for C17H26NO7P0.5H2O: C, 51.51; H, 6.87; N, 3.53. Found: C, 51.31; 
H, 6.66; N 3.59.  HRMS (FAB, glycerol): Calcd for C17H27NO7P (MH
+
) 388.1525; found 





butanoic acid (4-A). 
(2R,S)-2-Amino-4-{(S)-1-[N-(carboxymethyl)carbamoyl]propyl(methyl)-(RP*)-phosphono}-
butanoic acid (4-B). 
Compound 4 was prepared from 16 (324 mg, 0.495 mmol) by the same procedure as 
described for the synthesis of 2a and was purified by medium-pressure reversed-phase column 
chromatography (ODS-S-50B) with a linear gradient of 5 to 55% methanol in H2O. The 
ninhydrin-positive fractions (TLC, butan-1-ol/acetic acid/H2O, 5:2:2) were collected and 
lyophilized to afford the SP* isomer (4-A) (68.1 mg, 41%, slow-eluted isomer, eluted at 30% 
methanol) and the RP* isomer (4-B) (21.5 mg, 13%, fast-eluted isomer, eluted at 10% methanol) 
each as a colorless solid. 
Compound 4-A (a mixture of two diastereoisomers). 
1
H-NMR (300 MHz, D2O):δH 
4.92-4.79 [m, 1H, CH(OP)CONH], 4.05 (d, J = 18.0 Hz, 1H, Gly-Ha), 3.98 (d, J = 18.0 Hz, 1H, 
Gly-Hb), 3.90-3.82 [m, 1H, NH2(CO2H)CH(CH2)2P], 3.82 (d, 
3
JHP = 12.0 Hz, 3H, CH3OP), 
2.27-2.01 (m, 4H, CH2CH2P), 1.93 (dq, J = 7.2 and 6.6 Hz, 2H, CH3CH2), 0.98 (t, J = 7.2 Hz, 
3H, CH3). 
31
P-NMR (121 MHz, D2O): δP 35.09. IR (KBr) 3419 (br), 2976, 1732, 1664, 1539, 
1448, 1406, 1346, 1219, 1043, 1001, 893, 827, 775 cm
−1
. Anal. calcd for C11H21N2O8P0.8H2O: 
C, 37.25; H, 6.42; N, 7.90. Found: C, 37.21; H, 6.55; N, 7.98. HRMS (FAB, glycerol): Calcd for 
C11H22N2O8P (MH
+
) 341.1114; found 341.1114. 
Compound 4-B (a mixture of two diastereoisomers). 
1
H-NMR (300 MHz, D2O):δH 
4.90-4.78 [m, 1H, CH(OP)CONH], 4.04 (d, J = 17.7 Hz, 1H, Gly-Ha), 3.98 (d, J = 17.7 Hz, 1H, 
Gly-Hb), 3.89-3.83 [m, 1H, NH2(CO2H)CH(CH2)2P], 3.79 (d, 
3
JHP = 11.1 Hz, 3H, CH3OP), 
2.26-2.02 (m, 4H, CH2CH2P), 1.91 (dq, J = 7.5 and 6.6 Hz, 2H, CH3CH2), 0.97 (t, J = 7.5 Hz, 
3H, CH3). 
31
P-NMR (121 MHz, D2O): δP 35.04. IR (KBr) 3428 (br), 2978, 1728, 1658, 1540, 
 53 
1448, 1406, 1348, 1223, 1040, 1003, 895, 827, 773 cm
−1
. HRMS (FAB, glycerol): Calcd for 
C11H22N2O8P (MH
+
) 341.1114; found 341.1116. 
 
4.2.33. (S)- Benzyl 2-(benzyloxycarbonyl)but-3-enoate (18).
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Detailed synthetic procedure and the spectral data are written in Supplementary data. 
 
4.2.34. (S)-Benzyl 2-(N-benzyloxycarbonylamino)-4-[2-(tert-butoxycarbonyl)- 
ethylhydroxyphosphinyl]butanoate (20). 





, 830 mg, 10.0 mmol) in methanol (9.3 mL) was added 
triethylborane (4.00 mL of 1 M solution in THF, 4.00 mmol) at room temperature. The mixture 
was stirred vigorously open to air. After stirring for 5 h, the reaction was concentrated in vacuo 
to remove the solvent. The residual oil was partitioned between 10% aqueous KHSO4 (30 mL) 
and ethyl acetate (40 mL). The aqueous layer was extracted with ethyl acetate (2  40 mL), and 
the combined the organic layers were dried over anhydrous Na2SO4. The solvent was removed in 
vacuo to afford the phosphinic acid 19 (1.51 g, 97%) as a colorless oil. TLC 
(CH2Cl2/methanol/acetic acid, 80:20:1, cerium sulfate) Rf = 0.4, single spot. 
1
H-NMR (300 MHz, 
CDCl3): δH 11.5 (br s, 1H, P-OH), 7.41-7.19 (m, 10H, 2  Ph), 6.95 (d, 
1
JHP = 533 Hz, 1H, P-H), 
5.14 and 5.07 (2  s, 4H, 2  PhCH2O), 4.42 (br t, 1H, NH), 2.05-1.53 (m, 4H, CH2CH2P). 
31
P-NMR (121 MHz, CDCl3): δP 36.39. The crude phosphinic acid 19 was used for the next 
reaction without further purification. 
Compound 19 was dissolved in dry CH2Cl2 (15 mL) under argon. N,O-Bis 
(trimethylsilyl)acetamide (2.50 g, 12.0 mmol) and tert-butyl acrylate (564 mg, 4.40 mmol) was 
added successively to the solution, and the mixture was stirred at room temperature for 22 h. The 
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reaction mixture was cooled to 0 C and quenched with ethanol (3 mL) plus two drops of 
trifluoroacetic acid. The mixture was allowed to warm to room temperature. After stirring at 
room temperature for 30 min, the solvent was removed in vacuo. Ethyl acetate (70 mL) was 
added to the residue, and the resulting solution was washed successively with 10% aqueous 
KHSO4 and sat. NaCl, and was dried over anhydrous Na2SO4. The solvent was removed in 
vacuo to afford the crude dialkylphosphinic acid 20 (2.43 g) as a colorless oil. TLC 
(CH2Cl2/methanol/acetic acid, 80:20:1, cerium sulfate) Rf = 0.6 (ca. 80% purity). 
1
H-NMR (300 
MHz, CDCl3): δH 8.22 (br, 1H, P-OH), 7.38-7.24 (m, 10H, 2  Ph), 5.15 and 5.08 (2  s, 4H, 2  
PhCH2O), 4.40 [m, 1H, NH(CO)CH(CH2)2P], 2.45 (dt, 
3
JHP = 11.4 Hz, J = 8.4 Hz, 2H, 
PCH2CH2CO2
t
Bu), 2.14 and 1.92 (2  m, 2H, CHCH2CH2P), 1.90 (m, 2H, CH2CO2
t
Bu), 1.66 (m, 




P-NMR (121 MHz, CDCl3): δP 57.72. IR (NaCl) 3356 
(br), 2978, 1728, 1533, 1456, 1367, 1250, 1215, 1155, 1049, 976, 847, 739, 698 cm
−1
. HRMS 
(FAB, NBA): Calcd for C26H35NO8P (MH
+
) 520.2100; found 520.2106. The crude 20 was used 
for the next reaction without further purification.   
 
4.2.35. (S)-Benzyl 2-(N-benzyloxycarbonylamino)-4-{2-[N-(benzyloxycarbonylmethyl)- 
carbamoyl]ethyl(hydrogen)phosphino}butanoate (23). 
Crude compound 20 (2.43 g, ca. 4.0 mmol) was dissolved in a mixture of trifluoroacetic acid 
(10 mL) and CH2Cl2 (10 mL) at 0 C. The solution was stirred at room temperature for 7 h.  
Trifluoroacetic acid was removed in vacuo, followed by two cycles of azeotropic evaporation 
with toluene. The resulting residue was dissolved in ethyl acetate (80 mL), washed successively 
with 1 N HCl and sat. NaCl, and died over anhydrous Na2SO4. The solvent was removed in 
vacuo to afford the carboxylic acid 22 (1.88 g, 102%) as a pale yellow oil. To a solution of crude 
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22 in CH2Cl2 (50 mL), was added glycine benzyl ester monotosylate (8) (1.48 g, 4.40 mmol), 
1-hydroxybenzotriazole monohydrate (HOBtH2O) (594 mg, 4.40 mmol) and 
N,N-diisopropylethylamine (2.07 g, 16.0 mmol) at 0 C with stirring. Reaction was initiated by 
adding EDC (3.07 g, 16.0 mmol). After stirring at room temperature for 5 h, the reaction mixture 
was concentrated in vacuo to remove CH2Cl2. Ethyl acetate (100 mL) was added to the residue, 
and the resultant solution was washed successively with 1 N HCl, sat. NaHCO3 and sat. NaCl, 
and was dried over anhydrous Na2SO4. After removal of the solvent in vacuo, the residue was 
purified by flash column chromatography (4% methanol and 0.5% acetic acid in CH2Cl2) to 
afford 23 (1.23 g, 50% from 18) as a pale yellow oil. TLC (CH2Cl2/methanol/acetic acid, 80:20:1, 
cerium sulfate, Rf = 0.5). 
1
H-NMR (300 MHz, CDCl3): δH 10.23 (br, 1H, OH), 7.38-7.00 (m, 16H, 
3  Ph and NH), 5.14 and 5.11 (2  s, 4H, 2  PhCH2O), 5.08 and 5.03 (2  d, J = 12 Hz, 2H, 
PhCHaHbOCONH), 4.39 [m, 1H, NH(CO)CH(CH2)2P], 3.99 and 3.97 (2  s, 2H, Gly-HaHb), 
2.53 (dt, 
3
JHP = 14.7 Hz and J = 7.8 Hz, 2H, PCH2CH2CONH), 2.14 and 1.95 (2  m, 2H, 
CHCH2CH2P), 1.95 (m, 2H, PCH2CH2CONH), 1.72 (m, 2H, CHCH2CH2P). 
31
P-NMR (121 
MHz, CDCl3): δP 54.60. IR (NaCl) 3321 (br), 2949, 1743, 1718, 1533, 1456, 1394, 1340, 1254, 
1192, 1047, 970, 825, 739, 698 cm
−1
. Anal. calcd for C31H35N2O9P: C, 60.98; H, 5.78; N, 4.59. 
Found: C, 60.69; H, 5.83; N, 4.57. 
 
4.2.36. (S)-Benzyl 2-(N-benzyloxycarbonylamino)-4-{2-[N-(benzyloxycarbonylmethyl)- 
carbamoyl]ethyl(phenyl)-(RP,SP)-phosphino}butanoate (24). 
Oxalyl chloride (699 mg, 5.51 mmol) was added to a solution of 23 (840 mg, 1.38 mmol) 
and one drop of DMF in dry CH2Cl2 (10 mL) at 0 C. After stirring at room temperature for 1 h, 
toluene was added to the reaction, and the volatiles were evaporated. The resulting residue was 
 56 
dissolved in dry CH2Cl2 (10 mL), and phenol (259 mg, 2.75 mmol) in dry CH2Cl2 (2 mL) was 
added to the solution. The solution was cooled to 0 C, and dry Et3N (209 mg, 2.06 mmol) was 
added to initiate the reaction. The consumption of 23 was monitored by TLC 
(CH2Cl2/methanol/acetic acid, 80:20:1, cerium sulfate, Rf = 0.5), and the formation of product 
was confirmed by TLC (ethyl acetate/hexane, 5:1, cerium sulfate, Rf = 0.4). After stirring at 
room temperature for 2 h, the reaction mixture was concentrated in vacuo. The residue was 
dissolved in ethyl acetate (100 mL) and was washed successively with 1 N HCl and sat. NaCl, 
and was dried over anhydrous Na2SO4. After removal of the solvent in vacuo, the residue was 
purified by flash column chromatography (3% methanol in CH2Cl2) to afford the phosphinate 
ester 24 as a mixture of two diastereoisomers (524 mg, 55%, a pale yellow oil). 
1
H-NMR (300 
MHz, CDCl3): δH 7.37-7.08 (m, 20H, 4  Ph), 6.61 (br t, 1H, amide NH), 5.92 (br d, J = 7.8 Hz) 
and 5.84 (br d, J = 7.5 Hz) (1H, carbamate NH), 5.18-5.06 (m, 6H, 3  PhCH2O), 4.40 [m, 1H, 
NH(CO)CH(CH2)2P], 4.07-3.90 (m, 2H, Gly-H), 2.54 [m, 2H, PCH2CH2CONH], 2.28-1.76 [m, 
6H, PCH2CH2CONH and CHCH2CH2P]. 
31
P-NMR (121 MHz, CDCl3): δP 56.68 and 56.48. IR 
(NaCl) 3276 (br), 2949, 1747, 1718, 1541, 1491, 1456, 1254, 1196, 1045, 924, 825, 741, 696 
cm
−1
. Anal. calcd for C37H39N2O9P: C, 64.72; H, 5.72; N, 4.08. Found: C, 64.44; H, 5.49; N 4.05. 
 
4.2.37. (S)-2-amino-4-{2-[N-(carboxymethyl)carbamoyl]ethyl(phenyl)-(RP*,SP*)- 
phosphino}butanoic acid (5). 
The phosphinate ester 24 (211 mg, 0.307 mmol) was dissolved in a mixture of methanol (20 
mL) and H2O (4 mL) containing acetic acid (92.3 mg, 1.54 mmol). Hydrogen gas was passed 
through the solution in the presence of 5% Pd/C for 2.5 h at room temperature. The consumption 
of 24 was monitored by TLC (ethyl acetate/hexane, 5:1, cerium sulfate, Rf = 0.3), and the 
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formation of product was confirmed by TLC (butan-1-ol/acetic acid/H2O, 5:2:2, ninhydrin, Rf = 
0.35). The reaction mixture was filtered through Celite, and the filtrate was evaporated. The 
residue was purified by medium-pressure reversed-phase column chromatography on 
ODS-S-50B. The column was eluted (6 mL/min) with a linear gradient of 5 to 55% methanol in 
H2O.  The UV-positive (254 nm) fractions containing the product (TLC, butan-1-ol/acetic 
acid/H2O, 5:2:2, ninhydrin) were collected and lyophilized to afford 5 as a mixture of two 
diastereoisomers (22.8 mg, 20%, a colorless solid). 
1
H-NMR (300 MHz, D2O): δH 7.46 (dd, J = 
7.5 and 7.5 Hz, 2H), 7.31 (t, J = 7.5 Hz, 1H) and 7.22 (d, J = 7.5 Hz, 2H) (Ph) 3.80 [t, J = 5.1 Hz, 
1H, NH(CO)CH(CH2)2P], 3.73 (s, 2H, Gly-H), 2.64 [m, 2H, PCH2CH2CONH], 2.39 [dt, 
2
JHP = 
13.5 Hz, J = 8.1 Hz, 2H, PCH2CH2CONH], 2.32-2.03 (m, 4H, CHCH2CH2P). 
31
P-NMR (121 
MHz, D2O): δP 62.53 and 62.48. IR (KBr) 3431 (br), 3068, 1647, 1491, 1406, 1200, 1072, 1024, 
928, 833, 769, 692 cm
−1





4.3. Enzyme Assay 
4.3.1. General 
The hydrolytic activity of human GGT was measured by using 4.0 M 
7-(N--glutamylamino)-4-methylcoumarin (-Glu-AMC) as substrate at 25˚C and pH 5.5.39 
Assays were initiated by adding 10 L enzyme stock solution to 100 mM succinate-NaOH buffer 
(pH 5.5) in a total volume of 1 mL containing 100 L of -Glu-AMC stock solution (40 M in 
water) at 25˚C (the final -Glu-AMC concentration of 4.0 M).  The release of AMC was 
monitored continuously for 10 min with a Hitachi F-2000 spectrophotometer
 
(350 nm excitation, 
440 nm emission). AMC concentrations
 






concentration (C): F/C = 0.11 nM-1. The fluorescence 
intensity was proportional to the concentration of AMC up to 2.0 M. The Michaelis constant 
(Km) for -Glu-AMC of human GGT was determined as 12.6 μM under these conditions. The 
hydrolytic activity of E. coli GGT was measured under the same conditions, except that the final 
substrate concentration was 0.2 M. The Km value for -Glu-AMC of E. coli GGT was 
determined as  under the same conditions. 
 
4.3.2. Time-dependent inhibition assay 
The inhibition of GGT was measured under pseudo-first order rate conditions. Reaction was 
initiated by adding enzyme to a preincubated mixture of varying concentrations of the inhibitor 
and the substrate (the final concentrations of 4.0 and 0.2 M of -Glu-AMC for human and E. 
coli GGT, respectively) in 100 mM sodium succinate buffer (pH 5.5) at 25°C. Time-dependent 
inhibition of the enzyme was followed by monitoring the release of AMC continuously for 10 
min. The resulting concave progress curves were analyzed by fitting the data to the first-order 
rate equation (1) to calculate the observed pseudo-first-order rate constants for enzyme 
inactivation (kobs) using the KaleidaGraph v.3.5 program package (Synergy Software). 
 
                  [P] = [P]∞[1-exp(-kobs t)]     (1) 
 
where [P] and [P]∞ are the concentrations of AMC formed at time t and at time approaching 
infinity, respectively. Since the plot of kobs vs. inhibitor concentration ([I]) exhibited no 
saturation under standard inhibitor concentrations, the second-order rate constant for enzyme 
inactivation (kon) was calculated according to the equation (2) derived from the kinetic 






                       kobs= kon[I]/(1+[S]/Km)        
(2) 
 
where S is the substrate -Glu-AMC; [S] and Km are 0.2 and 0.2 M (E. coli GGT), and 4.0 and 
12.6 M (human GGT). 
 
4.4. Ion-Spray Mass Spectroscopy. 
The mass spectra were recorded on a Sciex API-3000 mass spectrometer (PE Sciex) 
interfaced with an ion-spray ion source. The E. coli GGT (600 g) was inactivated by incubation 
with 2a-A (1.7 mM) in 50 mM Tris-HCl buffer (pH 8.0) (total volume 100 L) at 37 ˚C for 20 
min or with 2a-A (4 mM) for 3 h. The activity of the partially or completely inactivated enzyme 
was measured by hydrolysis of -Glu-AMC. The small subunit of the inactivated enzyme was 
isolated by reversed-phase HPLC (COSMOSIL 5C18-AR-300, 4.6  150 mm) and was 
lyophilized as previously described.
70
 The lyophilized small subunit was dissolved in a mixture 
of 100 L of 0.1% formic acid and 100 L of acetonitrile, and was injected directly into mass 
spectrometer using a syringe (1.46 mm inside diameter) at a flow rate of 2.5 L/min. The 
quadrupole was scanned over a range of 500-2000 atomic mass units (amu) with a step size of 
0.1 amu and a dwell time of 0.2 ms. Ion-spray voltage was set at 5 kV, and orifice potential was 
60 V. Data analysis were performed using the BioMultiView program (PE Sciex).   
 
E  +  S
Km
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Figure 1.  Peptidyl phosphorus esters 2a-g, 3, 4 and 5 as mechanism-based inhibitors of GGT. 
 
Figure 1.  
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Figure 2.  Separation of diastereoisomeric pairs (A, B) of 2f with MPLC. 
See Experimental Procedures for conditions of chromatography. 

















Figure 3.  
 
Figure 3.  Typical time-dependent inhibition of GGT by 2a-A at pH 5.5 with 
γ-Glu-AMC as substrate. (A) Progress curves for reactions catalyzed by human GGT 
with 4.0 μM γ-Glu-AMC in the presence of varying concentration of 2a-A: (a) 0, (b) 4, 
(c) 10, (d) 12, (e) 16 and (f) 20 μM.  (B) Progress curves for reactions catalyzed by E. 
coli GGT with 0.2 μM γ-Glu-AMC in the presence of varying concentration of 2a-A: 
(a) 0, (b) 10, (c) 20, (d) 30, (e) 40 and (f) 60 μM. The formation of product AMC was 








Figure 4.  Stereochemistry of the attack of the catalytic nucleophile of 
human GGT (Thr residue) on the chiral phosphorus of the inhibitor 2f-A 









Figure 5.  Mass spectra of E. coli GGT small subunit (GGTS) 
incubated with 2a-A. (A) 0 mM, (B) 1.7 mM, 20 min, (C) 4.0 









Scheme 1: Proposed catalytic mechanism of GGT (A) and inhibition of GGT by the 
mechanism-based inhibitor 1 (B). Compound 1 is a mixture of stereoisomers with respect 










































Scheme 4.  Synthesis of phosphinate ester 5. 
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(Lα, SP*, Lα’), (Lα, RP*, Dα’), 
(Dα, SP*, Lα’), (Dα, RP*, Dα’) 
2a, c-f, 3 
and 4 
Peak A Two diastereoisomers (Lα, SP*, Lα’), (Dα, SP*, Lα’) 
Peak B Two diastereoisomers (Lα, RP*, Lα’), (Dα, RP*, Lα’) 
2b Four stereoisomers 
(Lα, SP*), (Lα, RP*),  
(Dα, SP*), (Dα, RP*) 
2g 
Peak A Two diastereoisomers (Lα, RP*, Dα’), (Dα, RP*, Dα’) 
Peak B Two diastereoisomers (Lα, SP*, Dα’), (Dα, SP*, Dα’) 
5 Two diastereoisomers (Lα, SP*), (Lα, RP*) 
a
 The ratio of stereoisomers is almost equal (1 : 1) in each case.
 
b
 Stereochemistry [ex. (Lα, SP*, Lα’)] is indicated in the order of the distal α-carbon of the 
glutamate moiety (Lα or Dα), the chiral phosphorus (SP* or RP*) and the proximal α-carbon of the 
peptidyl moiety (Lα’ or Dα’). Inhibitory active stereoisomers [ex. (Lα, SP*, Lα’)] are shown in bold 
(see Sections 2.5 and 2.6). 
c
 See Section 2.5. 
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Table 2.  Inhibitory activities of peptidyl phosphonate diesters 1,
39
 2a-g, 3, 4 and phosphinate 














Human GGT E. coli GGT 
1 DL-Abu-Gly 75 ± 3
c
 80 ± 2
c
 
2a L-Abu-Gly 145 ± 5.0 109 ± 2.9 
2b Gly-Gly 44.5 ± 2.5 80.6 ± 1.2 
2c L-β-ClAla-Gly 40.3 ± 0.59 188 ± 14 
2d L-β-IAla-Gly 43.6 ± 2.0 98.4 ± 2.9 
2e L-Phe-Gly 4.44 ± 0.28 389 ± 24 
























5 Gly-Gly 1.35 ± 0.11 NI
g
 
acivicin – 0.40 ± 0.02
h





 The activities of peak A (a mixture of two diastereoisomers, Table 1) are shown for 2a, 2c-g, 3 
and 4. The inhibitory activities of peak B are also shown for 2f and 2g (footnote e). The 
inhibitory activities of peak B were extremely low (see Sections 2.5 and 2.6). For compound 2b, 
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the activities of a mixture of four stereoisomers (two sets of enantiomers, Table 1) were 
determined. Compound 5, the phosphinate version of 2b, was a mixture of two diastereoisomers 
(Table 1). 
b
 Second-order rate constant for enzyme inactivation (see Section 4.3.2). 
c
 Ref. 39. 
d
 No inactivation at 1 mM. 
e
 Inhibitory activity of Peak B (Table 1) 
f
 Error limit was not determined due to duplicate measurements 
g
 No inactivation at 1.5 mM.  
h




Figure 1.  Peptidyl phosphorus esters 2a-g, 3, 4 and 5 as mechanism-based inhibitors of GGT. 
 
Figure 2.  Separation of diastereoisomeric pairs (A, B) of 2f with MPLC. 
For conditions of chromatography, see Section 4.2.29. 
 
Figure 3.  Typical time-dependent inhibition of GGT by 2a-A at pH 5.5 with γ-Glu-AMC as 
substrate. (A) Progress curves for reactions catalyzed by human GGT with 4.0 μM γ-Glu-AMC 
in the presence of varying concentration of 2a-A: (a) 0, (b) 4, (c) 10, (d) 12, (e) 16 and (f) 20 μM.  
(B) Progress curves for reactions catalyzed by E. coli GGT with 0.2 μM γ-Glu-AMC in the 
presence of varying concentration of 2a-A: (a) 0, (b) 10, (c) 20, (d) 30, (e) 40 and (f) 60 μM. The 
formation of product AMC was monitored continuously by fluorescence (see Section 4.3.2). 
 
Figure 4.  Stereochemistry of the attack of the catalytic nucleophile of human GGT (Thr 
residue) on the chiral phosphorus of the inhibitor 2f-A (A to B) as a model for catalyzed reaction 
of glutathione (C to D). 
 
Figure 5.  Mass spectra of E. coli GGT small subunit (GGTS) incubated with 2a-A.  
(A) control without inhibitor, (B) 1.7 mM of 2a-A, 20 min, (C) 4.0 mM of 2a-A, 3 h. 
 
Scheme 1: Proposed catalytic mechanism of GGT (A) and inhibition of GGT by the 
mechanism-based inhibitor 1 (B). Compound 1 is a mixture of stereoisomers with respect to the 
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ethyl side chain (see also Table 1). 
 
Scheme 2.  Synthesis of α-hydroxycarboxamides 9a-g and α-hydroxyester 11. 
 
Scheme 3.  Synthesis of phosphonate diesters 2a-g, 3 and 4. 
 




Spectral data for known compounds 7a, c, e-g, 9b, 11, 13 and 18 




H-NMR (300 MHz, CDCl3): δH 4.28 [dd, J = 6.9 and 4.5 Hz, 1H, CH(OH)COOH], 1.92 (dqd, J 
= 13.8, 7.2 and 4.5 Hz, 1H, CH3CHaHb), 1.77 (dqd, J = 13.8, 7.2 and 6.9 Hz, 1H, CH3CHaHb), 
1.02 (t, J = 7.2 Hz, 3H, CH3). 
 




H-NMR (300 MHz, CDCl3): δH 4.64 [t, J = 3.6 Hz, 1H, CH(OH)COOH], 3.94 (dd, J = 11.6 and 
3.6 Hz, 1H, CH3CHaHb), 3.88 (dd, J = 11.6 and 3.6 Hz, 1H, CH3CHaHb). 
 




H-NMR (300 MHz, CDCl3): δH 7.35-7.21 (m, 5H, Ph), 4.52 [dd, J = 7.3 and 4.2 Hz, 1H, 
CH(OH)COOH], 4.27 (br, 1H, OH), 3.22 (dd, J = 13.9 and 4.2 Hz, 1H, PhCHaHb), 3.00 (dd, J = 









H-NMR (300 MHz, CDCl3): δH 4.28 [dd, J = 7.5 and 4.2 Hz, 1H, CH(OH)COOH], 1.93-1.80 
[m, 1H, CH3(CH2)2CHaHb], 1.78-1.63 [m, 1H, CH3(CH2)2CHaHb], 1.54-1.28 (m, 4H, 
CH3CH2CH2), 0.93 (t, J = 7.1 Hz, 3H, CH3). IR (NaCl) 3451 (br), 2956, 1716, 1647, 1458, 1269, 








H-NMR (300 MHz, CDCl3): δH 4.28 [dd, J = 7.2 and 4.2 Hz, 1H, CH(OH)COOH], 3.9-2.1 (br s, 
1H, OH), 1.93-1.80 [m, 1H, CH3(CH2)2CHaHb], 1.78-1.63 [m, 1H, CH3(CH2)2CHaHb], 1.54-1.28 
(m, 4H, CH3CH2CH2), 0.93 (t, J = 7.2 Hz, 3H, CH3). IR (NaCl) 3435 (br), 2958, 1732, 1635, 





4.2.7. Benzyl 2-(2-hydroxyacetamido)acetate (9b). 
1
H-NMR (300 MHz, CDCl3): δH 7.39-7.29 (m, 5H, Ph), 7.28 (br t, 1H, NH), 5.16 (s, 2H, 
PhCH2O), 4.11 [d, J = 5.7 Hz, 2H, CH2(OH)CONH], 4.09 (d, J = 6.0 Hz, 2H, Gly-H) 3.97 (br, 
1H, OH). IR (NaCl) 3390 (br), 2941, 1747, 1660, 1539, 1196, 1124, 1078, 739, 698 cm
−1
. The 
spectral data supported the structure of compound 9b. 
 




H-NMR (300 MHz, CDCl3): δH 4.19 [ddd, J = 7.2, 5.7 and 4.2 Hz, 1H, CH(OH)COOMe], 3.79 
(s, 3H, CH3O), 5.47 (d, J = 5.7 Hz, 1H, OH), 1.86-1.73 [m, 1H, CH3(CH2)2CHaHb], 1.72-1.56 [m, 
1H, CH3(CH2)2CHaHb], 1.47-1.26 (m, 4H, CH3CH2CH2), 0.91 (t, J = 6.6 Hz, 3H, CH3). IR (KBr) 









H NMR (300 MHz, CDCl3): δH7.3-7.4 (m, 10H, 2  Ph), 5.46 (br d, 1H, J = 8.1 Hz, NH), 5.24 
(d, J = 12 Hz, 1H, PhCHaHbO), 5.18 (d, J = 12 Hz, 1H, PhCHaHbO), 5.12 (s, 2H, PhCH2OCON), 
4.53 [m, 1H, CH(CH2)2P], 2.1-2.7 (m, 4H, CH2CH2P).  
31
P NMR (121 MHz, CDCl3) δP 49.2. 
 
4.2.33. (S)- Benzyl 2-(benzyloxycarbonyl)but-3-enoate (18).
S6
 
Cupric acetate monohydrate (2.26 g, 11.3 mmol) was added to a suspension of 
(S)-5-benzyloxy-4-(benzyloxycarbonylamino)-5-oxopentanoic acid (17) (21.0 g, 56.6 mmol) in 
dry benzene (500 mL). The mixture was stirred at room temperature for 1 h under argon.  
Freshly purified lead tetraacetate (50.1 g, 113 mmol) was added, and the mixture was stirred for 
another 1 h at room temperature. The mixture was heated under reflux for 12 h. After filtering 
the reaction mixture through Celite, the filtrate was diluted with ethyl acetate (1000 mL) and was 
washed three times with H2O and once with sat. NaCl. The organic layer was dried over 
anhydrous Na2SO4. After removal of solvent in vacuo, the residue was purified by flash column 
chromatography (10% ethyl acetate in hexane) to afford the (S)-vinylglycine derivative 18 (7.41 
g, 40%) as a colorless solid. 
1
H-NMR (300 MHz, CDCl3): δH 7.41-7.27 (m, 10H, 2  Ph), 5.92 
[ddd, J = 16.8, 10.2 and 5.4 Hz, 1H, CHCH=CH2] 5.47 (br d, J = 7.5, 1H, NH), 5.36 (dd, J =16.8 
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and 1.5 Hz) and 5.27 (dd, J =10.2 and 1.5 Hz) (2H, CH=CH2), 5.19 and 5.12 (2  s, 4H, 2  
PhCH2O), 4.99 [dd, J = 7.5 and 5.4 Hz, 1H, NH(CO)CHCH=CH2]. IR (NaCl) 3313 (br), 3033, 
1743, 1508, 1456, 1338, 1267, 1213, 1176, 1076, 1051, 989, 924, 737, 696 cm
−1
. Anal. calcd for 
C19H19NO4: C, 70.14; H, 5.89; N, 4.31. Found: C, 70.27; H, 5.98; N. 4.29. 
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Figure S1. The electron density map around the active site of E. coli GGT in complex with 
2a-A. 
A 2Fo-Fc map at 1.0  (light blue) calculated from 1.9 Å resolution data contoured is overlaid on 
the stick model of GGT in complex with 2a-A, where the Rcryst and Rfree values of the model are 
0.206 and 0.236, respectively. Oxygen, nitrogen, phosphorus atoms are colored in red, blue and 
orange, respectively. Carbon atoms in 2a-A and in Thr391 are colored in light blue and green, 
respectively. Polypeptide chains of E. coli GGT except for the active site Thr391 are colored in 












Figure S2. Inhibition of human GGT by phenyl ester 2a and methyl ester 4. 
The enzyme reactions were conducted with 4.0 μM γ-Glu-AMC as substrate in the presence of 4 
(1 mM) or 2a (0.1 mM). The formation of product AMC was monitored continuously by 
















Figure S3. Time-dependent inhibition of human GGT by phosphinate 5. 
The enzyme reactions were conducted with 4.0 μM γ-Glu-AMC as substrate in the presence of 
varying concentration of 5: (a) 0, (b) 500, (c) 1000, and (d) 1500 μM. The formation of product 
AMC was monitored continuously by fluorescence (see Section 4.3). 
 
